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1. The amyloid cascade hypothesis 
In 1984, Glenner and Wang published a landmark report identifying the 
cerebrovascular amyloidogenic protein from patients with Alzheimer’s disease 
(AD) 1. One year later, the amyloid protein from brain parenchyma of 
individuals with AD or Down syndrome (DS) was characterized, showing that 
the cerebrovascular and parenchymal amyloid protein share the same origin 2. 
The amyloid protein from AD and DS is derived from the amyloid precursor 
protein (APP) 3. These findings formed the basis of the amyloid cascade 
hypothesis. It proposes that amyloid-β (Aβ) deposits in the brain drive multiple 
downstream effects and eventually lead to neurodegeneration 4–7 (Fig. 1). 
Microglia activation is downstream of Aβ aggregation, but it also could be the 
driving force for the disease progression when microglia functions are 
compromised 8 (Fig. 1). The amyloid cascade hypothesis moved the focus 
from descriptive research to mechanistic studies and is now the most widely 
accepted basis for drug development. 
The most powerful evidence supporting the amyloid cascade hypothesis 
comes from human genetics. DS patients (trisomy 21) have three copies of 
chromosome 21, where the APP gene locates. These patients often develop 
dementia due to AD complete with the two main AD pathological features, 
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amyloid plaques and neurofibrillary tangles, at early age 9. Moreover, DS 
patients with a third copy of chromosome 21 lacking the APP gene do not 
exhibit plaque and tangle pathologies 10.  
 
Fig. 1 The major pathological events in AD proposed by the amyloid cascade 
hypothesis  
Accumulated Aβ initiates downstream effects, including glial cells activation and neuronal 
tau aggregates. The serial events finally lead to neurodegeneration.  
 
2. Proteolytic processing of the amyloid precursor protein 
APP is a type-I transmembrane protein 3. APP undergoes proteolytic 
processing to generate multiple fragments, including the pathogenic Aβ 
peptides. Three processing pathways were discovered; the anti-amyloidogenic 
pathway, the amyloidogenic pathway and the η-secretase pathway 11,12 (Fig. 2). 
In the anti-amyloidogenic pathway, a disintegrin and metalloproteinase 10 
(ADAM10), also known as α-secretase, cleaves APP to generate soluble 
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APPα (sAPPα) and membrane-bound CTFα (C83) 13. Subsequently, 
γ-secretase processes CTFα to liberate p3 into the lumen and APP 
intracellular domain (AICD) into the cytosol 11. γ-secretase is a large protein 
complex with four essential subunits: nicastrin (NCT), anterior pharynx 
defective 1a (APH-1a) or APH-1b, presenilin enhancer-2 (PEN-2) 14–19 and the 
catalytic subunit presenilin 1 (PS1) or PS2 20–25. p3 is a truncated form of Aβ 
lacking the N-terminal amino acid 1-16, and it is considered as a 
non-pathogenic peptide 26. Alternatively, Aβ is generated via the 
amyloidogenic pathway. β-site APP-cleaving enzyme 1 (BACE1) cleaves 
full-length APP to generate soluble APPβ (sAPPβ) and a slightly longer form of 
membrane-bound CTFβ (C99) 11,27–30. The CTFβ is also processed by 
γ-secretase to liberate pathogenic Aβ and AICD 11. In the η-secretase pathway, 
an additional cleavage site was identified primarily at 504-505 of APP695 
12. 
MT5-MMP exerts this cleavage, although it might not be the unique 
η-secretase enzyme 12. With this additional cleavage, sAPPη and CTFη are 
generated. Subsequently, CTFη is further processed by α-secretase or BACE1 
to release Aη-α or Aη-β 12 (Fig. 2).   
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Fig. 2 Processing of the amyloid precursor protein  
Anti-amyloidogenic pathway: APP is sequentially cleaved by α-secretase and γ-secretase 
to liberate sAPPα, p3 and AICD. Amyloidogenic pathway: APP is sequentially processed by 
BACE1 and γ-secretase to secrete sAPPβ and Aβ and to release AICD. η-secretase pathway: 
η-secretase cleaves the full-length APP to generate sAPPη and CTFη. CTFη is further cleaved 
by α-secretase or BACE1. APP: amyloid precursor protein; sAPP: soluble amyloid precursor 
protein; AICD: APP intracellular domain; CTF: C terminal fragment. 
 
3. Mutations associated with familial Alzheimer’s disease 
Soon after the identification of APP, mutations were found in familial AD 
(FAD) patients. The first identified APP mutation was V717I (reference isoform: 
APP 770 amino acid), close to the C-terminus of Aβ peptide 31. It elevates the 
Aβ42 / Aβ40 ratio by increasing formation of the peptide Aβ42, which is more 
prone to aggregate 32. Thereafter, additional mutations in APP were found, 
some of which alter the proteolytic cleavage of APP or Aβ peptide aggregation 
properties. For example, the Swedish mutations substitute asparagine (N) and 
leucine (L) for lysine (K) and methionine (M) (KM670/671NL) 33–35. The 
Swedish mutations strongly enhance total Aβ production 33–35. The Arctic 
mutation (APP E693G) substitutes glycine for glutamic acid, resulting in a 
faster aggregation rate of Aβ42 
36. In addition to pathogenic mutations, a very 
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rare protective coding mutation (A673T) has been identified in Icelanders 
(Icelandic mutation) 37. In vitro studies show that this protective mutation 
reduces Aβ production by about 40% 37 and alters the aggregation properties 
of either Aβ40 
38 or Aβ42 
39 peptides. A673T carriers have 28% less plasma Aβ40 
and Aβ42 than non-carriers 
40, indicating that lifelong Aβ suppression protects 
against AD.  
Most early-onset familial AD cases have mutations in PS1 41. PS1 and 
PS2 encode presenilins, the catalytic subunits of the γ-secretase 20–25. More 
than 180 mutations were reported in PS1. Most pathogenic PS1 mutations 
increase the proportion of longer Aβ species like Aβ42, which have higher 
aggregation properties leading to enhanced Aβ deposition in mid-life 42. For 
example, the L166P mutation in PS1 reduces Aβ40 production and dramatically 
increases the ratio of Aβ42 / Aβ40 
43. Patients with the L166P mutation show 
early-onset AD and have numerous neuritic plaques throughout the cortical 
region 44. Some presenilin mutations, like the FAD-causing mutation L435F in 
PS1, are loss-of-function mutations and decrease total Aβ production without 
significantly altering the level of Aβ42 
45. This provides evidence that the loss of 
functional presenilin and not the accumulation of Aβ underlies FAD 45. 
However, the nearly inactive PS1 L435F mutation primarily produces the 
highly amyloidogenic Aβ43 
46. Substantial amounts of Aβ43-positive plaques 
were detected in brains of AD patients with PS1 L435F mutations, indicating 
that the large amount of Aβ43 produced in L435F mutation carriers might 
induce FAD rather than by a loss of γ-secretase function 46. The pathogenic 
 - 6 - 
 
and protective mutations strongly support that Aβ dyshomeostasis is 
necessary and sufficient to cause AD.  
 
4. Neuropathology of Alzheimer’s disease  
In a short report, Dr. Alois Alzheimer described the neuropathological 
features of the brain of Auguste D. The brain showed atrophy along with the 
major lesions, plaques and tangles, which we now know as the two major 
pathological hallmarks for AD 47,48.  
The accumulation of amyloid plaques in CNS is the unique feature for AD. 
Senile plaques are extracellular deposits containing mainly the Aβ40 and Aβ42 
peptides, although Aβ43 is detected in some mutation carriers (Fig. 3 A & B) 
46,49. Based on morphology, plaques are classified into two main categories: 
diffuse plaques and dense-core plaques, also known as neuritic plaques. 
Dense-core plaques can be easily stained by several dyes like Congo red, 
Thioflavin-S and Methoxy-X04, which mainly bind to β-sheet structure. 
Abnormal axons called dystrophic neurites are frequently found around the 
neuritic plaques. These contain paired helical filaments 49,50, degenerating 
mitochondria and mitochondria-derived autophagosomes 51. Ubiquitin and 
lysosomal-associated membrane protein 1 (LAMP1) are also accumulated in 
most of these dystrophic neurites 52,53, indicating that retrograde trafficking and 
lysosomal function might be affected. AD related proteins like APP and BACE1 
are found in dystrophic neurites as well, suggesting that axonal transport 
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defects accelerate Aβ production locally 54,55. Other pathological features, for 
example, activated microglia 56, reactive astrocytes 57, and synaptic and 
neuronal loss 58,59, are associated with neuritic plaques. These features 
suggest that neuritic plaques are closely related to neuronal injury.  
Unlike neuritic plaques, diffuse plaque usually can be detected by 
immunohistochemistry using antibodies against Aβ 60. Most of them lack the 
accompanying dystrophic neurites and gliosis 49,61. Diffuse plaques are 
frequently detected in cognitively normal elders 49,61. These pathological 
changes might be the first indication of the disease progression because they 
may later develop into neuritic plaques 62. Therefore, the cognitively normal 
elders with diffuse plaques are considered to be in the presymptomatic stage 
62.  
In addition to the parenchymal accumulation, Aβ also deposits in the 
vessel walls to form cerebral amyloid angiopathy (CAA). The major component 
of CAA is Aβ40 
49,61. Aβ40 usually accumulates in the walls of capillaries, small 
arteries in grey matter and arterioles of the leptomeninges 49,61. About 20% of 
AD patients are CAA negative 49.  
Neurofibrillary tangles (NFTs) are the second important feature of AD, 
although they do not exclusively appear in AD cases (Fig. 3 A & C). NFTs can 
be also found in other tauopathies, like Pick disease and certain forms of 
frontotemporal dementia 63. NTFs are intracellular aggregates containing 
misfolded and hyperphosphorylated microtubule-associated protein tau (p-tau) 
64. In the physiological situation, tau is a highly soluble protein that promotes 
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the assembly of the microtubule network 63. The abnormal phosphorylation of 
tau changes its conformation and causes it to dissociate from microtubules 
and accumulate into somatodendritc compartment 49. Tau phosphorylation 
also promotes self-aggregation 65.  
In addition to these two main pathological hallmarks, AD brains also 
exhibit broad glial responses. Activated microglia and astrocytes are 
associated with neuritic plaques. Microglia activation markers, for example 
microglial lysosomal protein CD68 and cell surface protein CD11c, are 
increased with the accumulation of neuritic plaques in entorhinal cortex 66. 
However, even after amyloid plaque burden reaches a plateau, microgliosis 
continues to increase linearly 67, indicating that glial responses are associated 
with both amyloid plaques and neurofibrillary tangles. The brain’s innate 
immune system actively responses to any change within the CNS, and these 
reactions are a double-edged sword (discussed in later chapter). 
 
Fig. 3 Neuropathological hallmarks in Alzheimer’s diseases 
A. Silver staining highlights amyloid plaques and neurofibrillary tangles; B. Amyloid 
plaques presented by immunostaining using anti-Aβ antibody; C. Neurofibrillary tangles 
highlighted by immunostaining using anti-phosphorylated tau antibody. Figure adapted from 
49
. 
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5. The role of microglia in Alzheimer’s disease 
Microglia are the resident innate immune cells of the central nervous 
system (CNS) and account for about 5-20% cells of the total mouse brain 68. 
They originate from progenitors in the embryonic yolk sac that migrate into the 
brain during development 69,70. In the resting stage, microglia appear to be 
ramified with multiple thin processes that constantly monitor the neighboring 
area 71. In response to small injury like microlesions, microglial processes 
rapidly protrude toward and around the injury site 72. Long-term stimulations, 
for example, amyloid plaques and neurofibrillary tangles, induce morphological 
changes in microglia from ramified to amoeboid shapes 73 and changes in 
microglial gene expression and microglial functions 74,75. How do microglia 
contribute to AD progression? Are they protective or detrimental to the 
disease? 
Recent genome-wide association studies (GWAS) and whole-exome 
microarray experiments identified variants of multiple genes that are 
specifically expressed or highly enriched in microglia that increase the risk for 
late onset Alzheimer’s disease (LOAD), including TREM2, ABCA7, CD33, CR1, 
MS4A, PLCG2, and ABI3 76,77. These genetic data indicate that microglia are 
not a bystander of AD, but rather actively contribute to the disease 
progression.  
Reduced microglia function is deleterious in AD. An important function of 
microglia is the engulfment and clearance of apoptotic cells and protein 
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aggregates. The phagocytic capacity of microglia is compromised by risk 
variants in the gene encoding triggering receptor expressed on myeloid cells 2 
(TREM2; discussed in next chapter). Another AD risk variant in CD33 
increases the expression level of CD33, which negatively regulates microglia 
phagocytic capacity 78. Microglia constantly change their expression profiles in 
response to the extracellular environments. In mouse models with plaque 
pathology, three subpopulations were found: homeostatic, intermediate, and 
disease-associated microglia (DAM) 74. In the DAM, certain pathways are 
highly upregulated, for example, the TREM2-ApoE pathway, the phagocytic 
and the lipid metabolism pathways 74,75. Alternatively, homeostatic genes like 
P2RY12, TMEM119, and HEXB as well as some inhibitory checkpoints like 
CX3CR1 are downregulated in this subset of microglia 74,75. DAM closely 
interact with amyloid plaques and also actively engulf Aβ 74. Downregulation of 
CX3CR1 might be required for acquiring higher phagocytic capacity, as 
CX3CR1 signaling inhibits phagocytosis and CX3CR1-deficient mice show 
reduced Aβ deposition 79. Full activation of the DAM signature is 
Trem2-dependent 74. Trem2-deficient microglia stay in the intermediate state 
and lack plaque-clustering capacity, thus they cannot abrogate amyloid 
pathology-induced toxicity 74,80,81. In this context, DAM have protective 
functions that clear protein aggregates and damaged neurons, as well as 
shield amyloid plaque to reduce toxicity 74,80,81.  
Activated microglia can be also deleterious in AD. Although the increased 
phagocytic capacity of microglia is beneficial for clearing toxic aggregates, 
aberrant and excessive synaptic engulfment by microglia is detrimental. 
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Indeed, abnormal synaptic loss is the first sign for neurodegeneration and 
positively correlates with cognitive decline 82–84. During development, microglia 
shape neural circuits by eliminating redundant synapses. Developmental 
synaptic pruning mainly relies on the complement cascade and fractalkine 
CX3CR1-CX3CL1 interactions 85–87. Complement protein C3 and C1q tag 
immature synapses and mediate phagocytosis via C3 receptors expressed in 
microglia 86. During progression of AD, this developmental process appears to 
be re-activated. C3 and C1q are upregulated in AD mouse models, enhancing 
synaptic engulfment by activated microglia 84. This synaptic loss can be 
blocked by inhibition of C3, or its receptor, CR3 84.  
Another harmful aspect of microglial activation is the excessive secretion 
of inflammatory cytokines. Activated microglia release many factors, like the 
pro-inflammatory cytokines TNFα and IL-1β, microglial proteases, and 
neurotoxic reactive oxygen 88. High levels of the pro-inflammatory cytokines 
TNFα and IL1β suppress long-term potentiation and induce neurotoxicity 89. 
However, TNFα and IL1β can also be beneficial. Overexpression of either 
TNFα or IL1β reduces amyloid pathology 90,91. Another harmful aspect of 
activated microglia is that they also induce neurotoxic reactive astrocytes by 
secreting TNFα, IL-1α and C1q 92. These reactive astrocytes lack 
neuroprotective functions and induce death of neurons and oligodendrocytes 
92. 
Microglia activation induced by amyloid pathology is a double-edged 
sword. Activated microglia clear Aβ by elevating phagocytic capacity; however, 
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chronic interactions between microglia and Aβ induces proinflammatory 
cytokines and activates astrocytes, leading to neuronal damage. For 
developing therapeutic approaches that modify microglia functions, it is crucial 
to study how to promote microglial protective functions like phagocytosis and 
prevent harmful effects. 
 
Therapeutic strategies for Alzheimer’s disease 
The amyloid cascade hypothesis provides multiple intervention 
opportunities for modifying disease onset and progression. Inhibition and 
modification of β- and γ-secretases are straightforward strategies for lowering 
Aβ production. Anti-Aβ immunotherapy aims to increase Aβ clearance and is 
the most advanced treatment for AD in clinical trials.  
 
1. β-secretase inhibitors and γ-secretase inhibitors and 
modulators             
Because the last step for Aβ generation is mediated by γ-secretase 11, 
γ-secretase inhibition was a very attractive therapeutic approach. However, 
γ-secretase cleaves more than 90 intramembrane proteins other than APP, 
some of which are involved in important signaling cascades 93. For example, 
the γ-secretase cleavage-dependent Notch signaling pathway regulates cell 
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proliferation, differentiation, and apoptotic programs (Fig. 4) 94. Non-selective 
γ-secretase inhibitors, like semagacestat, have failed in clinical trials due to 
significant adverse events, including skin cancers, infections and 
gastrointestinal symptoms 95,96. To make matters worse, cognitive decline was 
accelerated in patients receiving semagacestat 96. These adverse events may 
be partially due to the non-selective inhibition of γ-secretase resulting in 
impaired Notch signaling 95. To avoid non-selective inhibition of γ-secretase 
function, γ-secretase modulators (GSMs) are in development. GSMs modulate 
the processivity of γ-secretase, thereby shifting the Aβ production line to 
shorter species 97.  
 
Fig. 4 Illustration of Notch proteolytic processing and signaling 
Notch is a cell surface protein that is first cleaved by α-secretase followed by cleavage by 
γ-secretase to generate the intracellular domain (ICD). Notch ICD translocates to the nucleus 
where it modulates target gene expression.  
 
Another therapeutic target of AD is β-secretase, also known as BACE1. 
BACE1 is the rate-limiting enzyme for Aβ generation. Similar to γ-secretase, 
BACE1 has many substrates 98. The non-selective inhibition of BACE1 might 
cause side effects due to affecting the biological functions of its substrates. 
Dendritic spine density and synaptic plasticity were reduced upon treatment 
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with a high dose of BACE inhibitors 99,100. These alterations result from 
abolishing the processing of seizure protein 6 99,100. Moreover, BACE inhibition 
alters APP processing, leading to an accumulation of Aη-α, which inhibits the 
neuronal activity in the hippocampus 12. A disruption of axonal organization in 
the hippocampus was found in adult conditional BACE1 knockout mice, 
suggesting adulthood complete BACE inhibition might cause deficits in the 
hippocampus, the region that is important for learning and memory 101. The 
on-target side effects induced by BACE inhibition might be responsible for the 
recent failure of the BACE inhibitor in a phase III clinical trial. In this trial, 
prodromal AD patients with positive amyloid positron emission tomography 
(PET) imaging were recruited for a two-year treatment with the BACE inhibitor 
verubecestat. Verubecestat caused a small but statistically significant 
cognitive deficit in a dose-dependent manner (Alzforum news 02 Nov 2018; 
https://www.alzforum.org). A lower dose of BACE inhibitor could be used to 
avoid the adverse effects, although this might only lower Aβ production less 
than 50% (Alzforum news 02 Nov 2018; https://www.alzforum.org). In 
preventive trials with subjects at risk for AD, low doses of BACE inhibitors 
might have a chance to prevent or delay AD onset, as even small decreases in 
Aβ can be protective. For instance, the protective APP rare variant A673T 
lowers plasma Aβ levels by 28%, indicating lifelong small Aβ reductions are 
sufficient to prevent AD 40. Additionally, the cocktail therapy combining a low 
dosage of BACE inhibitors with anti-Aβ immunotherapy can be considered. 
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2. Anti-Aβ immunotherapy for Alzheimer’s disease 
A pivotal study by Schenk and colleagues initiated the anti-Aβ 
immunotherapy approach for AD. Immunization of young, pre-plaque PDAPP 
mice (Table 2) 102 with Aβ42 prevented amyloid plaque pathology 
103. Amyloid 
plaque burden was largely reduced in aged PDAPP mice after immunization 
103. Most importantly, immunotherapy prevented age-related learning and 
memory deficits in an AD mouse model 104. These striking preclinical studies 
inspired the first active immunotherapy clinical trial for AD, which involves 
intravenous injections of amyloid peptides in patients. In the AN1792 trial 
(Table 1), Aβ1-42 was injected into mild to moderate AD patients. However, it 
had to be terminated at early 2002 after 6% of subjects developed symptoms 
of T cell–mediated aseptic meningoencephalitis and leukoencephalopathy 
105,106. This might be due to the presence of T-cell epitopes in the middle region 
and the carboxyl terminus of Aβ42 
107. Furthermore, no significant improvement 
on cognitive performance was detected in patients with an antibody response 
106. A follow-up study from the AN1792 phase I trial examined eight 
vaccine-recipients neuropathologically 108. Aβ load was significantly lower in 
the Aβ42 –injected group compared to placebo controls, and the degree of Aβ 
reduction correlated with mean anti-Aβ antibody titer 108. Despite Aβ removal in 
all examined patients in the Aβ42 –injected group, they had severe end-stage 
dementia at the time of death 108. This study is often cited in arguments against 
the amyloid cascade hypothesis. However, most patients had moderate 
dementia at the time of vaccination, and plaque removal at this stage may not 
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be sufficient to reverse the established deficits. Another follow-up study from 
the AN1792 trial showed that about 4.6 years after immunization with Aβ42, 
most of the antibody responders (17 of 19 individuals tested) still had a low but 
detectable anti-Aβ titer 109. Moreover, these individuals showed reduced 
functional decline compared to placebo-treated subjects, although brain 
volumes were the same between the two groups 109. This follow-up study may 
suggest that, although anti-Aβ antibody does not prevent neurodegeneration, 
daily-life performance of antibody responders may improve. However, the 
small sample size limited clear conclusions from antibody responders.  
The second-generation of Aβ vaccines are currently being tested in 
clinical trials (Table 1). The main goals of the second-generation vaccines are 
to avoid the T-cell mediated cellular immune response and to increase the 
antibody response titer. For example, ACC-001 (Aβ1-6) from Janssen/Pfizer, 
was tested in two phase IIa trials. Mild to moderate AD patients (n=245) were 
enrolled to validate the safety, tolerability and anti-Aβ IgG immunogenicity 110. 
Amyloid-related imaging abnormalities (ARIAs), which represent vasogenic 
edema or cerebral microhemorrhages, occurred in 0.8% of patients 110,111. 
Aβ1-6 immunization induced higher and sustained anti-Aβ IgG titers. In this 
phase IIa study, cognitive performance did not increase in treatment groups 
compared to placebo, although the functional measurements are exploratory 
110. 
Different from active immunotherapy, passive immunotherapy for AD 
involves immunizing patients with anti-Aβ antibodies. Peripheral injection of 
 - 17 - 
 
anti-Aβ antibody 3D6 decreased amyloid burden in an AD mouse model 112. 
Although the antibody level in plasma is relative high, only 0.1-0.2% of 
antibody enters the CNS and decorates amyloid plaques, allowing Aβ 
clearance via Fcγ receptor-mediated microglial phagocytosis 112. Compared to 
active vaccines, passive immunization is easier to stop if adverse events occur 
and allows for more easily managed antibody concentrations in serum. 
However, disadvantages to passive immunity are high cost and repeated 
injections. Several monoclonal antibodies (mAb) are testing in advanced 
clinical trials (Table 1).  
Bapineuzumab is the humanized version of mouse mAb 3D6 and targets 
the Aβ1-5 epitope 
113,114. The biggest complication in the phase II trial of 
Bapineuzumab was ARIAs, which are associated with high antibody doses 
and the  ApoE 4 allele 113.  ApoE 4 is the strongest genetic risk factor for 
AD 115 and it has been linked to higher degree of cerebral amyloid angiopathy 
(CAA) in AD mouse models and in AD patients 116. It is possible that vascular 
integrity is further compromised in ApoE 4 carriers after anti-Aβ 
immunotherapy. The primary efficacy analysis did not show significant 
differences; however, a post hoc study analyzing the patients who received all 
infusion and non-ApoE 4 carriers showed potential cognitive and functional 
improvements 117. In the phase III trial of Bapineuzumab, ApoE 4 carriers 
received lower antibody dosage. Unfortunately, no statistically significant 
cognitive improvement was observed in treatment groups 113,114. ARIAs limited 
the usage of high antibody dosage in patients, especially in the ApoE 4 
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carriers. One possible mechanism for ARIAs is that the fast removal of Aβ from 
cerebral vessels compromised vessel integrity due to strong Fc effector 
function 113. By introducing mutations in the Fc region, the second generation 
of Bapineuzumab has less binding efficacy to the Fcγ receptor and 
complement C1q 118. It decreases antibody effector functions, including 
reduced antibody–FcR interaction-triggered cytotoxicity, slower phagocytosis, 
and reduced complement cascade-induced cell death 118. 
Gantenerumab, a humanized IgG1 anti-Aβ mAb, preferentially binds to Aβ 
fibrils and oligomers 119. Peripheral administration of gantenerumab in 
PS2APP mice (Table 2) reduced amyloid plaque burden and prevented new 
plaque formation by eliciting microglia-mediated Aβ clearance 119. The phase I 
trial of gantenerumab shows that it was well toleranted in human subjects: only 
six participants in the high dosage group showed ARIAs 120. However, 
gantenerumab did not meet the primary outcome in the phase II/III trial 121. 
There were no significant differences in multiple cognitive tests between 
treated and placebo subjects 121, though subgroup analysis indicated that it 
might benefit patients with fast disease progression during the treatment, 
especially the ones with high exposure to gantenerumab 121. This may suggest 
that high doses of gantenerumab would potentially provide clinical benefits. 
Serious adverse events were also reported in placebo groups 121. Again, the 
prevalence of ARIAs was dose- and ApoE 4 allele-dependent 121. Currently, 
gantenerumab is being used in the Dominantly Inherited Alzheimer Network 
(DIAN), which is a prevention trial enrolled with individuals at risk for 
developing autosomal dominant AD 114. 
 - 19 - 
 
Aducanumab is another human IgG1 mAb. It was developed by screening 
human B-cell clones from healthy aged individuals for reactivity against 
aggregated Aβ. Upon peripheral injection of aducanumab into Tg2576 mice 
(Table 2), Aβ depositions were decreased, including the thioflavinS-positive 
compact plaques 122. The number of amyloid plaque-clustered microglia was 
increased upon aducanumab treatment, suggesting anti-Aβ antibody 
treatment elicited microglia-mediated plaque clearance 122. In the phase 1b 
trail, intravenous infusion of aducanumab reduced amyloid plaque in dose- 
and time-dependent manner in prodromal or mild AD patients measured by 
amyloid PET 122. In the highest dose (10 mg/kg) group, amyloid PET signal 
was comparable to the negative scan after 54 weeks of treatment 122. Although 
this trial was not powered for clinical analysis, the exploratory analysis of 
efficacy indicates a slower cognitive decline in the one-year treatment group 
122. The correlation between amyloid plaque removal and cognitive 
improvement might suggest microglia-mediated antibody-dependent plaque 
clearance is important for clinical benefits. Similar to other mAbs, dose- and 
ApoE ε4 allele-dependent ARIAs were the most common adverse effect, and 
the occurrence is higher than for many other mAbs 114,122. Now, two phase III 
clinical trials were launched to test the efficacy of aducanumab in prodromal or 
mild AD patients 114. 
Small amount of antibodies enter the CNS and elicit amyloid clearance by 
multiple potential mechanisms, including (i) triggering Fcγ receptor-mediated 
Aβ clearance by microglia, (ii) binding and removing Aβ in plasma to generate 
a net efflux from CNS to plasma, and (iii) binding to Aβ oligomers to inhibit the 
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toxicity 123. These mechanisms are not mutually exclusive, and different 
antibodies might rely more on particular mechanisms. For example, 3D6 (the 
murine form of bapineuzumab), gantenerumab and aducanumab elicit 
clearance of plaque by microglia via Fcγ receptor-mediated uptake 112,119,122. 
For this type of antibody, the phagocytic capacity of microglia is crucial for the 
optimal outcome of immunotherapy.   
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Table 1 Amyloid-related active and passive immunization for Alzheimer's disease 
Active 
Trial Aβ target Stage Status 
AN1792 full-length Aβ1-42 peptide Phase 2 Terminated; No improvement 
ACC-001 Aβ1-7 peptide Phase 2 Terminated; Not reported 
Affitope AD02 
six amino acids mimotope 
mimics the N-terminus of Aβ Phase 2 Terminated; Not reported 
ABvac 40 C terminus of Aβ40 Phase 2 
Ongoing; safe, well-tolerated, antibody titers in 
phase I trail 
CAD106 
Aβ1-6 peptide coupled to a Qβ 
virus-like particle Phase 2/3 
Ongoing; safe, well-tolerated, antibody titers in 
phase I and II trail; No report on cognitive 
measurement. 
UB 311 
Aβ1-14 linked to different 
helper T-cell peptide epitopes Phase 2 Ongoing; Not reported 
Passive 
Trial Monoclonal Antibody/Target Stage Status 
Bapineuzumab 
(AAB-001) Humanized IgG1; Anti-Aβ1-5 Phase 3 Terminated; No cognitive improvement; ARIA 
Bapineuzumab 
(AAB-003) 
Humanized IgG4 to minimize 
ARIA; Anti-Aβ1-5 Phase 1 
Terminated; safe, well tolerated; No significant 
changes in CSF biomarkers 
Crenezumab 
Humanized IgG4; 
Recognizes oligomeric and 
fibrillar Phase 3 
Terminated; The treatment is unlikely to have 
positive effects on cognition. It is studied in API*. 
Ponezumab 
Humanized IgG2a; Binds to 
the C terminal of Aβ Phase 2 





monomeric Aβ Phase 3 
Ongoing in DIAN and A4 Study*; No clinical 
improvement overall but slight improvement in 
patients with early AD 
Gantenerumab 
Human IgG1; High affinity to 
fibrillar Aβ Phase 3 
Ongoing; also used in DIAN; No clinical benefits 
overall but toward a benefit in high dose group with 
fast progression 
Aducanumab 
Human IgG1; Binds to 
aggregated forms of Aβ Phase 3 
Ongoing; dose-dependent amyloid removal and 
slowing cognitive decline in exploratory analysis 
 
 
* API: The Alzheimer’s Prevention Initiative; DIAN: Dominantly Inherited Alzheimer Network; 
A4 Study: Anti-Amyloid Treatment in Asymptomatic Alzheimer's disease; ARIA: 
Amyloid-related imaging abnormalities; CSF: cerebral spinal fluid  
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 Triggering receptor expressed on myeloid cells 2 
(TREM2) 
TREM2 is cell surface receptor exclusively expressed on myeloid cells 124. 
TREM2 is required for microglial functions, for example, phagocytosis, 
migration, and proliferation 125–129. Rare coding variants in TREM2 increase 
the risk of AD 130,131, implicating microglia as a pivotal factor in AD progression. 
In addition to disease progression, microglia functions are crucial for the 
outcome of immunotherapy. It is valuable for future immunotherapeutic 
approaches to study if and how TREM2 affects the efficacy of 
immunotherapeutic approaches.  
 
1. Expression and processing of TREM2  
TREM2 localizes at the short arm of chromosome 6 in humans and 
chromosome 17C3 in mice 132. Two isoforms of TREM2 are generated due to 
alternative splicing, encoding either membrane-bound TREM2 or soluble 
TREM2 (Fig. 5). In humans, the transcript variant 2 lacks the entire exon 4 
coding for the transmembrane region; hence, this transcript encodes soluble 
TREM2 (Fig. 5). In mouse, soluble TREM2 lacking the transmembrane region 
is generated due to alternative splicing at the 5’ end of the exon 4 133 (Fig. 5).  
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Fig. 5 Alternative splicing of TREM2 mRNA 
Alternative splicing of human TREM2 skips the entire exon 4 and shifts the reading frame 
of exon 5 (green) to generate transcript variant 2 lacking the coding information for the 
transmembrane region. In mouse, a different splicing acceptor site is used in the alternative 
spliced mouse TREM2, and it lacks the transmembrane domain due a frame shift (green). TM: 
transmembrane domain. 
 
The major transcript encodes the membrane-bound TREM2. The 
membrane bound TREM2 is a type I transmembrane glycoprotein, and it 
belongs to the immunoglobulin ‘superfamily’. It consists of a 
immunoglobulin-like ligand-binding region in its large extracellular domain, a 
transmembrane region and a very short intracellular domain (Fig. 6) 124,132. 
TREM2 is mainly expressed in the myeloid cell lineage, including 
macrophages, neutrophils, microglia, and osteoclasts 124. The expression level 
of TREM2 is tightly regulated; for example, proinflammatory stimuli 
lipopolysaccharide (LPS) reduces TREM2 expression in macrophages and 
microglia 129,134. TREM2 is highly upregulated in amyloid plaque-associated 
myeloid cells 81,128, suggesting that amyloid plaques are important inducers for 
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the expression of TREM2, although it is still unclear if this upregulation is 
directly induced by Aβ or by other signals in the near plaque region. 
Membrane-bound TREM2 undergoes regulated intramembrane 
proteolysis similar to APP. The large extracellular domain of TREM2 is shed by 
ADAM10/17, releasing soluble TREM2 (sTREM2) into the extracellular space 
(Fig. 6) 127. Since membrane-bound TREM2 is capable of inducing 
downstream signaling (discussed in the next section), TREM2 signaling can be 
blocked by this shedding. The remaining TREM2 CTF is further degraded by 
γ-secretase (Fig. 6) 135. When this degradation is impaired, the accumulated 
TREM2 CTF also interacts with the signaling adaptor protein DNAX-activating 
protein 12 (DAP12) (discussed in the next section). Thereby, the accumulated 
TREM2 CTF might limit the interaction between full length TREM2 and DAP12 
resulting in decreased TREM2 signaling 135. 
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Fig. 6 Illustration of membrane-bound TREM2 and DAP12 
TREM2 interacts with DAP12 through an electrostatic interaction between aspartic acid 
and lysine. DAP12 contains an immunoreceptor tyrosine-based activation motif (ITAM) for 
signaling. TREM2 is processed by ADAM10/17 and release the soluble TREM2. The 
membrane-attached fragment is further cleaved by γ-secretase for final degradation. 
 
2. The function of TREM2 in microglia 
TREM2 is a lipid sensor and it binds to anionic and zwitterionic lipids 125. It 
also binds to ApoE 136,137, ApoJ 136 and Aβ 138. Upon ligand binding, the signal 
transduction of TREM2 requires the adapter protein DAP12 (Fig. 6). Two 
cysteine residues in the short extracellular domain of DAP12 allow for the 
formation of homodimers by disulfide bridges 139. A negatively charged 
aspartic acid residue is located in the transmembrane segment of DAP12, 
which interacts with the positively charged lysine of TREM2 via electrostatic 
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interaction 140. In the cytosolic region, DAP12 has an immunoreceptor 
tyrosine-based activation motif (ITAM) for signaling 141 (Fig. 6). When ligands 
bind to TREM2, the tyrosine residues in the DAP12 ITAM motif are 
phosphorylated by Src kinases 124. The phosphorylated ITAM recruits and 
phosphorylates spleen tyrosine kinase (Syk) or/and Zeta chain-associated 
protein kinase 70 (ZAP70) to initiate downstream signal cascades 124. 
TREM2 signaling regulates several important microglial functions such as 
inflammation, phagocytosis, chemotaxis and microglial activation. 
TREM2/DAP12 signaling plays an anti-inflammatory role by inhibiting cytokine 
production in response to Toll-like receptors (TLRs) activation 129.  
TREM2/DAP12 signaling is important for phagocytosis. Human embryonic 
kidney cells 293 (HEK 293) and Chinese hamster ovary cells (CHO), the 
non-phagocytic cells, were capable of internalizing apoptotic cells and bacteria 
after TREM2 and DAP12 co-expression 127,142. TREM2 knockout (ko) microglia 
and macrophages engulf less bacteria, apoptotic neurons, Aβ fibers and 
amyloid plaques 127,136,142. However, TREM2-dependent Aβ phagocytosis is 
controversial. Two groups showed that the phagocytic uptake of Aβ in 
TREM2-deficient microglia is comparable to wt microglia 125,138. This 
discrepancy will be further discussed in the summary and general discussion 
chapter.  
TREM2 also regulates chemotaxis and injury response 143. When 
TREM2-deficient microglia are challenged by chemotactic signals, such as 
amyloid deposits, aging or focal laser injury, they are partially activated, and 
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their migration towards stimuli was impaired 74,143. Some homeostatic check 
point genes, such as P2RY12, TMEM119, CX3CR1, were downregulated; 
however, most of phagocytic and lipid metabolism genes related to DAM were 
unchanged 74. This may explain why they show impaired chemotactic motility 
and phagocytosis.  
TREM2 is crucial for maintaining microglia metabolism and autophagy 144. 
Mammalian target of rapamycin (mTOR) signaling, which is a central regulator 
of metabolism and autophagy, is impaired in TREM2-deficient phagocytes 144. 
These findings are in line with our results, showing that glucose metabolism 
was reduced in loss-of-function mutant TREM2 T66M knock-in (ki) mice 145. 
However, the reduced glucose consumption in TREM2 T66M ki mice may not 
only represent the metabolic defects in microglia. Since neurons and 
astrocytes are the main consumers of glucose, the metabolic status of neurons 
or astrocytes might be also altered in TREM2-deficient mice. TREM2 is 
exclusively expressed in microglia within the CNS, suggesting that metabolic 
changes in neurons or astrocytes might be mediated by sTREM2 generated by 
shedding of full length TREM2 (Fig. 6). 
sTREM2 can be detected in human plasma and cerebrospinal fluid (CSF) 
127,146. Two independent studies showed sTREM2 levels are higher in AD 
patients than in controls 147,148. With a detailed patient characterization, 
Suárez-Calvet and colleagues found that sTREM2 peaks in patients with mild 
cognitive impairment due to AD 149. Moreover, this increase positively 
correlated with the neurodegeneration markers total tau and 
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phosphorylated-tau in CSF 149. Using CSF samples from autosomal dominant 
AD patients, Suárez-Calvet and colleagues revealed that CSF sTREM2 levels 
are elevated at 5 years before the expected symptom onset and after Aβ 
deposition and neuronal injury 150. All these data suggest that sTREM2 could 
be an indicator for microglia activation in response to neuronal injury during 
disease progression 147–150.  
 
3. TREM2 variants are risk factors of Alzheimer’s disease  
Homozygous loss-of-function variants in TREM2 or DAP12 lead to a rare 
autosomal disorder called Nasu-Hakola disease (NHD) 151. NHD is a fatal 
disease characterized by bone and brain phenotypes. Patients with NHD have 
bone cysts, frequent bone fractions and joint pain. They also show 
frontotemporal dementia, followed by death in their fourth or fifth decade of life. 
Heterozygous mutations in TREM2, on the other hand, increase the risk for 
several neurodegenerative diseases, including AD, frontotemporal dementia, 
and Parkinson’s disease 130,131,152–154. Most of these variants locate at the 
immunoglobulin-like ligand-binding region, such as Q33X, Y38C, R47H, R62H, 
T66M, D78N (Fig. 6). The NHD-related homozygous mutation at position 191 
of the TREM2 gene changes glutamine 33 to a stop codon (Q33X), resulting in 
a premature truncated protein 155. The same mutation in a heterozygous state 
is significantly associated with AD 130 and frontotemporal dementia 152, which 
indicates that impaired TREM2 functions may promote disease onset and 
progression. Studies from certain variants, like T66M, indicate they result in a 
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loss of function suggesting that TREM2 has protective roles. TREM2 T66M 
maturation and transport are impaired, leading to a dramatic accumulation of 
mutant immature TREM2 in the endoplasmatic reticulum 127,145. Therefore, cell 
surface, mature TREM2, sTREM2 and TREM2 CTF are all reduced 127,145. 
TREM2 T66M ki mice show enhanced proinflammatory responses upon LPS 
stimulation 145, similar to TREM2 ko mice 129. The age-dependent microglia 
activation was reduced in TREM2 T66M ki mice as shown by a longitudinal 
study using the 18kD microglia activity tracer, translocator protein ligand 
(TSPO), for small animal PET (μPET) 145. In line with the TSPO μPET data, the 
number of microglial nodules, which are associated with removing 
myelin/axonal debris, was reduced in TREM2 T66M ki mice 145. Structural 
analysis suggests T66 is buried within the core of the immunoglobulin fold, and 
thus the T66M variant may impair protein folding (Fig. 6) 156. These data 
strongly support that T66M is a loss-of-function mutation and TREM2 is 
protective against disease progression.  
Although several variants of TREM2 contribute to a higher risk for AD 157, 
TREM2 R47H (rs75932628-T) is the most important disease variant, tripling 
the risk for AD 130,131. It is comparable to the strongest common genetic risk 
factor for LOAD, the ApoE ε4 allele 158,159. Structural analyses revealed that 
arginine 47 is required for stabilizing conformation and maintaining the positive 
charge binding surface 160. As a result, the R47H variant attenuates ligand 
(APOE, APOJ, Aβ etc.) binding 136,137 and TREM2 signaling 161. In line with 
these findings, overexpression of human TREM2 R47H in TREM2-/- : 5×FAD 
mice failed to rescue TREM2 loss-of-function phenotypes 162, indicating that 
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the R47H variant impairs TREM2 functions. Using the CRISPR/Cas9 
technique, Cheng-Hathaway and colleagues generated TREM2 R47H ki mice 
163. These mice showed a reduced TREM2 mRNA level and TREM2 
loss-of-function phenotypes, including reduced microgliosis, reduced TREM2 
upregulation in plaque-associated microglia and reduced microglial clustering 
around amyloid plaques 163. This may indicate that the TREM2 loss-of-function 
in R47H ki mice is due to TREM2 mRNA reduction.  
To study the impact of TREM2 loss-of-function on the onset and 
progression of AD pathology, TREM2-/- mice were crossed with different AD 
mouse models. TREM2 deficiency ameliorated plaque pathology in 
4-month-old APP/PS1 mice (Table 2) 128. However, in another AD mouse 
model, namely 5×FAD (Table 2), TREM2 deficiency worsens the amyloid 
burden in hippocampus at 8.5-month of age 125. Jay and colleagues attempted 
to clarify the conflict by studying the plaque pathology in TREM2-/- : APP/PS1 
mice at different ages 164. The results show that the plaque pathology is 
reduced in young but increased in old TREM2-deficient APP/PS1 mice 164. 
However, other studies showed that TREM2 deficiency has no impact on the 
burden of amyloid deposition, but the amyloid plaques are more diffuse and 
associated with more dystrophic neurites 80,81. The increased neuritic damage 
around amyloid plaques in TREM2 ko mice maybe due to lack of protective 
microglia barriers 80,81. Another factor that interferes with the amyloid 
aggregation is the Aβ co-aggregation protein, ApoE. ApoE is strongly 
upregulated in the subset of microglia with disease associated mRNA 
signature, which is in the vicinity of plaques 74. Interestingly, ApoE is heavily 
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reduced in TREM2 deficient microglia 75. Parhizkar and colleagues used an in 
vivo amyloid seeding paradigm to study how TREM2 modified amyloid plaque 
formation 165. At the plaque seeding stage, TREM2-dependent microglial 
activation limits plaque formation 165. Amyloidogenesis is limited by the 
phagocytic CD68-positive microglia clustered around the newly seeded plaque 
165. Meanwhile, the plaque-associated microglia upregulate ApoE in a 
TREM2-dependent fashion 75,165. Amyloid plaque aggregation and compaction 
might be promoted by TREM2-dependent microglia-derived ApoE, since ApoE 
is a well-described factor that accelerates Aβ accumulation and aggregation 
166–168. TREM2-deficiency worsens amyloid pathology at the plaque seeding 
stage due to lack of chemotaxis and phagocytosis; however, the difference on 
amyloid pathology is compensated by the lack of microglia-derived ApoE 
during plaque development 165. TREM2 may have protective functions at the 
seeding stage by reducing seeding activity.  
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Table 2 Research models (https://www.alzforum.org) 
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MAPT: microtubule-associated protein tau 
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Goals of the study  
Disease-associated rare coding variants in TREM2 most likely are 
loss-of-function mutations. At least some of the mutant proteins, such as T66M 
and Y38C, are misfolded and retained within ER 127. One of the major impacts 
of TREM2 loss-of-function on microglia is the phagocytic defect. A complete 
knockout of TREM2, as well as the T66M variant, reduce the ability of 
microglia to phagocytose Aβ fibers, bacteria and beads 127,145. Similarly, myelin 
debris removal is impaired in TREM2-/- animals after cuprizone-induced acute 
demyelination 169. The phagocytic defects of TREM2-deficient microglia may 
also influence the microglia-mediated antibody-dependent plaque clearance. 
Amyloid clearance is an essential prerequisite for potential cognitive 
improvement after anti- Aβ immunotherapy. The first goal of the thesis was to 
investigate if the efficacy of anti-Aβ immunotherapy dependent on TREM2 
activity and determine how the disease-associated variants T66M interfere 
with the immunotherapeutic outcome. Although T66M is a lost-of-function 
variant, it has been identified to cause FTD-like syndrome but not AD 170. The 
AD-associated TREM2 variant, namely R47H has been much less investigated. 
The second goal of my study was to generate TREM2 R47H ki mouse model 
and to understand the R47H related dysfunctions responsible for the 
enhanced risk for late onset AD.   
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Abstract 
Immunotherapeutic approaches are currently the most advanced 
treatments for Alzheimer's disease (AD). Antibodies against amyloid β-peptide 
(Aβ) bind to amyloid plaques and induce their clearance by microglia via Fc 
receptor-mediated phagocytosis. Dysfunctions of microglia may play a pivotal 
role in AD pathogenesis and could result in reduced efficacy of 
antibody-mediated Aβ clearance. Recently, heterozygous mutations in the 
triggering receptor expressed on myeloid cells 2 (TREM2), a microglial gene 
involved in phagocytosis, were genetically linked to late onset AD. Loss of 
TREM2 reduces the ability of microglia to engulf Aβ. We have now 
investigated if loss of TREM2 affects the efficacy of immunotherapeutic 
approaches. We show that anti-Aβ antibodies stimulate Aβ uptake and 
amyloid plaque clearance in a dose-dependent manner in the presence or 
absence of TREM2. However, TREM2-deficient N9 microglial cell lines, 
macrophages as well as primary microglia showed significantly reduced 
uptake of antibody bound Aβ and as a consequence reduced clearance of 
amyloid plaques. Titration experiments revealed that reduced efficacy of 
amyloid plaque clearance by TREM2 knockout cells can be compensated by 
elevating the concentration of therapeutic antibodies. 
Keywords: Alzheimer’s disease, immunotherapy, neurodegeneration, 
phagocytosis, TREM2.   
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Introduction 
Alzheimer's disease (AD) is the most abundant neurodegenerative 
disorder and threatens our ageing society. Therapeutic treatment is 
desperately required to slow progression of dementia. The amyloid cascade 1 
provides a number of opportunities to therapeutically interfere with disease 
onset and progression. Obvious targets are β- and γ-secretases, the two 
proteases, which generate the amyloid β-peptide (Aβ) from its precursor, the 
β-amyloid precursor protein (APP) 2. γ-secretase inhibition caused major side 
effects in a clinical trial, which were at least partially due to inhibition of its 
biological activity in Notch signaling 3. Similarly, recent findings may also 
indicate that inhibition of β-secretase may be problematic due to the 
accumulation of alternative neurotoxic APP derived fragments 4. Moreover, 
β-secretase has numerous brain specific substrates and their biological 
function may be disturbed upon inhibition of shedding 5–7. In fact, neuregulin-1 
signaling depends on biologically active β-secretase 8,9. Nevertheless, several 
β-secretase inhibitors are currently in late stage clinical development and if 
demonstrated to be safe may be of therapeutic value. The most advanced and 
very promising therapeutic approach is currently the anti-Aβ immunotherapy 10, 
a treatment strategy initiated after the pivotal report by Schenk et al. 11 
demonstrating its efficacy in amyloid plaque removal and reduction of memory 
decline in an animal model 12. After crossing the blood brain barrier anti-Aβ 
antibodies like 3D6 and others bind to amyloid plaques and trigger Fc-receptor 
mediated phagocytosis of plaques by microglia cells 13. Indeed, 11C-PiB 
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positron emission tomography (PET) revealed a significant reduction of 
amyloid deposition in patients treated with anti-Aβ antibodies 14,15. Although 
initially there was no obvious beneficial effect on memory, data from two recent 
clinical trials now suggest that immunotherapy may significantly slow memory 
decline 16. Moreover, a recent clinical trial using Aducanumab indicated that 
significant amyloid removal is required for clinical benefits suggesting a critical 
role of amyloid removal by microglia. Indeed, antibody-mediated clearance of 
amyloid plaques requires biologically active microglia cells 13. Recently it was 
reported that heterozygous mutations in the triggering receptor expressed on 
myeloid cells 2 (TREM2) increase the risk for AD, Frontotemporal Lobar 
Degeneration, Amyotrophic Lateral Sclerosis, and Parkinson's disease 17–24. 
We have shown that certain mutations in TREM2 such as p.T66M reduce the 
ability of microglia to phagocytose Aβ fibers, bacteria and beads due to 
impairment of TREM2 maturation and cell surface transport 25. Furthermore, a 
complete knockout of TREM2 also reduces the ability of primary microglia to 
phagocytose Aβ 25. Similarly, in a cuprizone-model for acute demyelination 
TREM2-deficient mice showed reduced phagocytic removal of myelin debris 26. 
However, in mouse models for AD pathology TREM2-deficiency resulted in 
inconsistent findings. Jay et al. reported a detrimental role of TREM2 in AD by 
demonstrating that its knockout leads to a reduction of the amyloid plaque load, 
inflammation, astrogliosis and tau phosphorylation 27. On the other hand, 
Wang et al. demonstrated that TREM2-deficiency enhanced amyloid plaque 
load 28. This discrepancy may be due to the use of different mouse models, but 
 - 49 - 
 
also due to the fact that microglial function may be differentially compromised 
depending on the time point one investigates amyloid pathology 29.  
It is well known that antibodies bound to amyloid plaques trigger 
Fc-receptors mediated Aβ clearance by microglia cells 13. We were interested 
if antibody-mediated Aβ clearance may be influenced by TREM2 function. To 
avoid confounding effects of different mouse models, time points of analysis 
and differences in progression of disease pathology, which in aggressive 
APP/presenilin overexpressing mouse models may even override microglial 
amyloid plaque clearance, we choose several independent models to 
quantitatively investigate TREM2-dependent antibody-mediated Aβ clearance 
under controlled conditions. We used CRISPR/Cas9 modified N9 microglial 
cell lines as well as bone marrow derived macrophages (BMDM) and primary 
microglia cells from wild-type (wt) or TREM2 knockout (ko) mice and 
investigated the potential of these cells for antibody-dependent phagocytosis 
of pre-formed Aβ fibrils or engulfment of antibody covered amyloid plaques 
from brain cryosections obtained from a mouse model for AD pathology. 
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Results 
1. TREM2-deficiency reduces uptake efficacy of 
antibody-bound Aβ by phagocytic cells 
To investigate a potential influence of TREM2-deficiency on 
antibody-mediated Aβ clearance, we first studied Aβ uptake in the microglial 
cell line N9 30. TREM2 mutant cell lines were generated using the 
CRISPR/Cas9 technology 31. We obtained a mutant cell line with a single 
nucleotide insertion (93_94insG) within the target site, which leads to a 
frameshift and an early stop codon that eliminates TREM2 expression (Fig. 
1A). Immunoblotting confirmed the loss of full-length, membrane-bound 
TREM2 as well as soluble TREM2 (sTREM2) in TREM2 mutant N9 cells (N9 
mu) (Fig. 1B). In line with our previous findings 25, loss of TREM2 significantly 
reduced uptake of pre-aggregated HiLyte™ Fluor 488 labeled Aβ42 (fAβ42) (Fig. 
1C). Cytochalasin D, an inhibitor of actin polymerization, was used as negative 
control. Addition of 5 μg/ml of antibody 2D8, an antibody raised to the 
N-terminus of the Aβ domain 32, significantly stimulated Aβ uptake in both N9 
wt and N9 mu, however phagocytosis remained less efficient in N9 mu (Fig. 
1C). As a negative control we used antibody 6687 raised to the C-terminus of 
APP 33. Although this antibody interacts with APP it fails to increase Aβ uptake 
demonstrating that the specific interaction of 2D8 with Aβ is required to trigger 
the uptake (Fig. 1C). 
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To investigate antibody-stimulated Aβ clearance in primary phagocytic 
cells we first used BMDM derived from TREM2 ko animals 34 or wt controls. 
Western blotting confirmed the absence of sTREM2 and full-length, membrane 
bound TREM2 in cells derived from TREM2 ko mice (Fig. 1D). We then studied 
fAβ42 uptake in the presence of 0, 1, 5, or 10 µg/ml of antibody 2D8 or a 
non-binding control antibody 6687. BMDM readily internalized fAβ42, which 
could be blocked entirely by addition of cytochalasin D (Fig. 1E). Consistent 
with our previous findings 25, BMDM derived from TREM2 ko mice showed a 
significantly reduced phagocytic activity compared to BMDM derived from wt 
mice (Fig. 1E). Phagocytosis of fAβ42 in wt BMDM could be intensively 
stimulated by antibody 2D8 with a maximum stimulation at 5µg/ml. Antibody 
6687 even at a high concentration of 10 μg/ml had only a very minor effect (Fig. 
1E). Although antibody 2D8 significantly stimulated uptake of fAβ42 even in 
TREM2 ko BMDM, phagocytosis was less efficient compared to wt at all 
antibody concentrations used (Fig. 1E). These findings suggest that fAβ42 
uptake is greatly stimulated upon antibody binding in both wt and TREM2 ko 
BMDM, however the overall uptake capacity is reduced in TREM2 ko BMDM. 
In line with that there was no significant change in the relative increase of 
antibody-stimulated uptake in both genotypes (Fig. 1F) suggesting that 
antibody-stimulated uptake per se is not reduced due to TREM2 deficiency. 
Next, we used the monoclonal antibody mAb11, a murine IgG2a antibody, 
which has similar amyloid binding properties like the therapeutically used 
human IgG1 anti-Aβ antibody Gantenerumab 35,36 and performed titration 
experiments in the fAβ42 uptake assay using BMDM derived from wt or TREM2
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ko mice. mAb11 but not an IgG2a isotype control (50 µg/ml) strongly 
stimulated phagocytosis of fAβ42 (Fig. 1G). Interestingly, even very low 
concentrations of 0.1 µg/ml, which may be reached in the brain by peripheral 
antibody administration, were sufficient to trigger fAβ42 uptake. Uptake 
plateaued at 20 µg/ml and could not be further enhanced by using antibody 
concentrations up to 50 µg/ml (Fig. 1G). In line with the data shown in Fig. 1C 
& E, fAβ42 uptake by BMDM derived from TREM2
 ko mice could be efficiently 
stimulated by increasing the amounts of mAb11 (Fig. 1G & H). However, again 
the phagocytic capacity never reached the level of wt BMDM even at the 
highest antibody concentration used (Fig. 1G). Thus, a monoclonal antibody 
with efficient target engagement similar to the therapeutically used 
Gantenerumab stimulates both TREM2 dependent and independent 
engulfment of fAβ42.  
To investigate if sTREM2 could rescue reduced fAβ42 uptake of BMDM 
derived from TREM2 ko mice in a non-cell autonomous manner we 
supplemented the culture media of wt and ko cells with increasing amounts of 
recombinant mouse sTREM2. sTREM2 even added at a 10-fold higher 
concentration as compared to its physiologically concentration in plasma of 
mice (approximately 10 ng/ml) did not rescue fAβ42 uptake efficacy of TREM2 
ko cells in the presence or absence of mAb11 (Fig. 1I). Thus, receptor 
mediated signaling in a cell autonomous manner appears to trigger fAβ42 
uptake. 
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Finally, we further confirmed our findings in primary microglia derived from 
wt or TREM2 ko mice. Western blotting confirmed the absence of sTREM2 and 
full-length, membrane bound TREM2 in primary microglia from TREM2 ko 
mice (Fig. 1J). In line with our previous findings 25, microglia from TREM2 ko 
mice showed significantly less uptake of fAβ42 (Fig. 1K). Again, phagocytosis 
was similarly stimulated by mAb11 in a concentration-dependent manner in 
both, microglia derived from wt and from TREM2 ko mice (Fig. 1K & L). In line 
with the above data derived from N9 cells and BMDM (Fig. 1C, E and G), total 
uptake capacity was reduced at each antibody concentration in TREM2 ko 
microglia (Fig. 1K).  
 
2. Increased Fcγ-receptors expression and enhanced Syk 
phosphorylation in TREM2-deficient BMDM 
To investigate if reduced phagocytic capacity but similar increases of 
antibody-stimulated uptake in the absence of TREM2 may be due to 
compensatory mechanisms, we first investigated expression of Fcγ-receptors 
(FcγR), which are of central importance for antibody-mediated phagocytosis. 
Compared to wt BMDM, cell surface FcγRI, FcγRIIB and (or) FcγRIII were 
significantly increased in TREM2 ko cells (Fig. 2A & B). Correspondingly, 
mRNA levels of the respective FcγR (I, IIB, III) were all significantly increased 
in TREM2 ko cells (Fig. 2C). mRNA level of FcγRIV was also increased but it 
did not result in enhanced cell surface protein level (Fig. 2A-C). To further 
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validate the compensatory mechanisms, downstream signaling was studied. It 
is well known that upon stimulation of TREM2 as well as Fcγ-receptors, Syk 
gets phosphorylated and activates a variety of downstream signaling cascades 
23,37,38. As expected, Syk phosphorylation strongly increases upon incubation 
of wt BMDM with 2D8-bound Aβ which was not the case when using an 
isotype-control antibody together with Aβ (Fig. 2D & E). Interestingly, 
phosphorylation of Syk is further increased upon stimulation with 
antibody-bound Aβ in the absence of TREM2 (Fig. 2D & E).  
Together with increased levels of FcγR this may suggest a compensatory 
increase of TREM2 independent antibody/antigen uptake pathways probably 
explaining why TREM2 ko cells still respond to increasing concentrations of 
anti-Aβ antibodies. 
 
3. TREM2-deficiency reduces antibody-mediated amyloid 
plaque clearance 
Next we used an ex vivo model (Fig. 3A), which would allow monitoring 
antibody-dependent amyloid plaque clearance under controlled and 
comparable conditions 13. We used cryosections of whole brains from 
APP/PS1 mice 16 at 6-months of age, a time point where these mice are known 
to exhibit a high amyloid plaque burden within the brain 16. mAb11, but not the 
isotype control, binds selectively to the methoxy-X04 positive amyloid plaques 
(Fig. 3B). When wt BMDM (Fig. 3C) or primary microglia (Fig. 3D) were added 
 - 55 - 
 
to brain sections pre-incubated with mAb11, we observed a clustering of CD68 
positive cells around methoxy-X04 labeled amyloid plaques. Moreover, cells 
clustering around amyloid plaques engulfed Aβ fibers, as shown by the 
intracellular methoxy-X04 staining, which partially co-localized with the 
lysosomal protein CD68 (Fig. 3C & D). 
We next used the ex vivo assay to investigate TREM2-dependent 
antibody-stimulated amyloid plaque clearance. When cryosections of 
APP/PS1 mice were incubated with BMDM derived from wt or TREM2 ko mice, 
a significant TREM2-dependent reduction of amyloid plaque clearance was 
observed (Fig. 4A & B). Upon pre-incubation of cryosections with mAb11 (1 
µg/ml), amyloid plaque clearance by wt BMDM was significantly stimulated 
(Fig. 4A & B). In line with the results in Fig. 1, TREM2-deficient BMDM were 
significantly less efficient in clearing amyloid plaques than wt BMDM under the 
same experimental conditions (Fig. 4A & B). Cell densities in the different 
experiments were similar, as assessed by CD68 staining on consecutive slices 
(Fig. 4C & D). Reduced amyloid plaque clearance by BMDM derived from the 
TREM2 ko animals upon antibody stimulation was confirmed by western 
blotting of total protein lysates generated from cryosections after termination of 
the experiment. In line with the experiments in Fig. 4A & B, mAb11 caused a 
stronger reduction of Aβ signals on western blots in the presence than in the 
absence of TREM2. However, even in the absence of TREM2, a reduction of 
Aβ was observed with mAb11 pre-incubation as compared to the no-antibody 
control (Fig. 4E).  
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4. Improvement of amyloid plaque clearance by elevated 
antibody concentrations 
We next titrated mAb11 with the aim to compare the efficacy of 
antibody-mediated TREM2-dependent amyloid plaque clearance. 
Cryosections from brains of APP/PS1 mice were pre-incubated with increasing 
concentrations of mAb11 from 0.001 µg/ml to 5 µg/ml before incubation with 
BMDM derived from wt or TREM2 ko mice. In line with the fAβ42 uptake assays 
described in Fig. 1, this revealed a concentration dependent clearance of 
amyloid plaques (Fig. 5A & B). Comparison of the extend of methoxy-X04 
positive amyloid labeling after clearance by BMDM derived from wt or TREM2 
ko mice demonstrates that antibody-mediated clearance can occur in the 
absence of TREM2 (Fig. 5A & B), similar to the uptake of fAβ42 shown in Fig. 1. 
However, the total capacity to engulf amyloid plaques is reduced in TREM2 ko 
BMDM (Fig. 5A & B). Of note, a statistically significant effect on amyloid plaque 
clearance is observed in TREM2 ko BMDM at 0.1 µg/ml, a concentration which 
is therapeutically reachable in brain by appropriate dose adjustment 35,36. 
Taken together, our finding suggests that patients with compromised TREM2 
function may require a higher dose of the therapeutic antibody to achieve 
efficient Aβ clearance.  
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Discussion 
A pivotal role of microglia and inflammatory mechanisms in AD and other 
neurodegenerative disorders, which was already emphasized early during AD 
research 39, was recently strongly supported by genetic evidence 24. 
Specifically, rare heterozygous mutations in TREM2, which within the brain is 
exclusively expressed in microglia cells, dramatically increase the risk for late 
onset AD in a magnitude similar to ApoE ε4 20,21. Although TREM2 is well 
known to be involved in phagocytosis and removal of apoptotic neurons 40–42 
the pathological consequences of a TREM2 loss-of-function in the context of 
AD pathogenesis is highly controversial. While Aβ was shown to be engulfed 
at least to some extend in a TREM2-dependent manner in cultured cells 25, 
experiments on mouse models for AD pathology reached surprising and 
opposite results. On the one hand, reduction of TREM2 ameliorated several 
aspects of AD pathology, including inflammation, astrocytosis and amyloid 
plaque burden 27 while on the other hand, TREM2-deficiency leds to 
exacerbated disease pathology including increased amyloid plaque burden 28. 
However, attenuated Aβ engulfment by microglia was thought to be due to 
reduced migration and survival and thus not directly associated with 
phagocytic activity of microglial cells 28. Our findings may now provide direct 
evidence that TREM2 is required at least partially for Aβ engulfment and 
clearance. Even in the absence of antibody stimulation we consistently find 
reduced Aβ uptake and amyloid plaque clearance in all model systems used. 
Potential survival deficits in TREM2 ko cells do not impact our results, since 
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uptake was measured after 2 hours of incubation in the phagocytosis assay. 
Moreover, equal amounts of cells were used in the ex vivo plaque clearance 
assay and cell density was assessed after termination of experiments ruling 
out differences due to survival or the total number of phagocytic cells.  
After antibody binding to Aβ, uptake and amyloid plaque clearance 
increase in a concentration-dependent manner in the presence or absence of 
functional TREM2, although the total uptake capacity of cells lacking TREM2 is 
reduced. This indicates that TREM2-independent Fcγ-receptor-mediated 
pathways are intact and used in addition to TREM2-dependent uptake 
mechanisms. Indeed, it has been shown previously that Syk phosphorylation is 
an important signaling event upon Fcγ-receptors activation in macrophage 
phagocytosis 37,43. Higher levels of FcγR and upregulated phosphorylated Syk 
in TREM2 ko BMDM upon stimulation with Aβ-2D8 immune complexes may 
therefore suggest a compensatory upregulation of TREM2-independent 
phagocytosis. 
Our findings might also indicate that direct effects of TREM2 on amyloid 
plaque clearance are difficult to assess in vivo since in the absence of an 
antibody stimulus Aβ uptake is 4-5 fold lower and probably difficult to quantify. 
In addition, the mouse models used to study the effects of TREM2 on amyloid 
plaque clearance not only highly overexpress APP but also express rather 
aggressive familial AD associated mutations, which may override modulatory 
effects of TREM2. Moreover, since TREM2 affects survival of microglial cells 
28,44, the age as well as the specific mouse model used for the investigation 
 - 59 - 
 
must be carefully considered. In that regard, it is interesting to note that at very 
early time points of amyloid plaque deposition Aβ accumulation was similar in 
wt and TREM2 ko mice, but TREM2 ko mice showed reduced microglia 
accumulations around amyloid plaques 45.  
Finally, our findings may be valid for future immunotherapeutic 
approaches. Anti Aβ immunotherapy is currently a promising and clinically 
advanced approach 10. It not only lowers the amyloid plaque load, but also 
prevents de novo deposition of plaques and stabilized memory deficits at least 
to some extend in two recently reported clinical trials 46. We now demonstrate 
that mAb11, a murine IgG2a antibody, which has similar amyloid binding 
properties like Gantenerumab 36 which is currently explored in clinical trials 35, 
significantly stimulates Aβ engulfment even in the absence of TREM2. For 
successful immunotherapy, knowledge on microglial activity and survival in 
individual patients may be crucial for optimal outcome of the treatment. In that 
regard we recently demonstrated that in AD patients, sTREM2 levels 
significantly increase very early before onset of AD and tend to decrease in 
later phases of the disease 47. In addition to CSF biomarkers, microglial PET 
imaging may be required similar to amyloid PET imaging used in the clinic to 
select patients for enrollment into clinical trials and to in vivo prove the effects 
of treatment on amyloid plaque load. If microglial function and survival are 
reduced during ageing in a TREM2-dependent manner, one may also 
speculate to modulate TREM2 activity. Moreover, in case of attenuated 
TREM2 function an increased dose of therapeutic antibodies may be required 
to compensate impaired plaque clearance.   
 - 60 - 
 
Materials and Methods 
1. Mice 
All animal experiments were performed in accordance to local animal 
handling laws. APP/PS1 and TREM2 knockout mice (TREM2 ko) 34were 
maintained on a C57BL/6J background. For bone marrow extraction, adult 
mice (from 2-months old to 12-months old, mixed gender) were euthanized by 
CO2 then sacrificed by cervical dislocation. For primary microglia culture, 
postnatal day P0-2 mice (mixed gender) were sacrificed by decapitation.  
 
2. CRISPR/Cas9‐mediated genome engineering in N9 
The murine microglia cell line N9 30 was maintained in Dulbecco’s 
modified Eagle’s medium (DMEM) + GlutaMAXTM (Life Technologies) with 10% 
(v/v) fetal calf serum (FCS; Sigma-Aldrich) and 100 U/ml penicillin, 100 µg/ml 
streptomycin. All cells were mycoplasmas free. N9 cells were transfected with 
pSpCas9(BB)-2A-Puro V2.0 (PX459; gift from Feng Zhang; Addgene plasmid 
# 62988) using the Nucleofector™ SF-Kit for 4D-Nucleofector™ (Lonza) 
according to manufacturer’s recommendations. 24 h post transfection, cells 
were selected with 4 µg/ml puromycin for 2 days. Single cell clones were then 
cultured with normal culture medium, followed by screening for genetic 
modifications in TREM2 by PCR amplification and missense detection using 
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T7 Endonuclease I (NEB). Mutations were confirmed by direct sequencing 
(GATC-Biotech).  
 
3. Bone marrow derived macrophages culture 
Bone marrow derived macrophages (BMDM) were prepared essentially 
as described before 48. Briefly, mice femurs and tibias were dissected and 
sterilized with 70% ethanol. The bones were flushed with a syringe filled with 
advanced RPMI 1640 (Life Technologies) to extrude bone marrow. Cell 
suspensions were filtered through a 100 μm cell strainer and incubated for 2 
min in ACK lysis solution (Thermo Fisher Scientific) to lyse red blood cells. The 
bone marrow cells were cultured and differentiated in advanced RPMI 1640 
supplemented with 2mM L-Glutamine, 10% (v/v) FCS, 100 U/ml penicillin, 100 
µg/ml streptomycin and 50 ng/ml murine M-CSF (R&D System) using 
non-tissue culture treated Petri dishes (BD Biosciences). Three days after 
seeding fresh murine M-CSF (final concentration of M-CSF 50 ng/ml) was 
added and media was changed at day 5 of culture. BMDM were used for 
experiments at day 7 in vitro. Immunostaining with CD68 (Fig. 3C and Fig. 4C) 
as well as flow cytometry (see below) using anti-CD11b antibody (Fig. EV1A) 
were used to confirm the identity of these cells. 
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4. Primary microglial culture 
Primary murine microglial murine cell cultures were prepared as 
previously described. Briefly, mixed glial cultures were prepared from the 
whole brain devoid meninges and cerebellum of P0-2 mice and cultured in 
DMEM with Glutamax I (Life Technologies), supplemented with 10% (v/v) FCS, 
100 U/ml penicillin and 100 µg/ml streptomycin. 50% of the medium was 
replaced every other day and 10 ng/ml murine M-CSF (R&D System) was 
supplemented at day 7 in culture. After 10 days in culture, cells were shaken at 
200 rpm for 30 min to isolate microglia. The medium containing microglia was 
pelleted at 200 g for 8 min and reseeded to corresponding plates for 
experiments. Cell identity was confirmed using anti-CD68 (Fig. 3D) and 
anti-CD11b (Fig. EV1B) antibodies. 
 
5. Flow Cytometry 
BMDM or primary microglial cells were suspended in FACS buffer (Hank's 
Balanced Salt Solution, no calcium, no magnesium; 0.2% bovine serum 
albumin; Thermo Fisher Scientific). Samples were labeled with anti-CD11b 
antibodies (M1/70), APC-Cy7® conjugated (1:100; Life Technologies) for 30 
min at 4 °C. Data were acquired using MACSQuant® VYB (Miltenyi Biotec) and 
analyzed by FlowJo software. 
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To quantify absolute expression levels for the different cell surface 
Fcγ-receptors (FcγR), BMDM were labeled with PE anti- FcγRII/III (1:100; BD 
Bioscience), PE anti- FcγRI (1:100; R&D System) or PE anti-FcγRIV (1:100; 
BD Bioscience) at 4 °C for 30 min. Data were acquired on a FACSVerse flow 
cytometer (BD, USA) and analyzed using FACSuite software (BD, USA). 
Absolute numbers of PE anti-FcγR molecules per cell were determined using 
QuantiBRITE (BD Bioscience) PE calibration beads following the analysis 
strategy according to the manufacturer’s protocol. Gates were set according to 
unlabeled and isotope controls. Absolute PE anti-FcγR molecules counts were 
performed per individual sample and normalized to the mean of the wt control 
group. 
 
6. Cell lysis and immunobloting 
Western blot analysis of membrane bound TREM2 was performed as 
previously described 25. For western blot analysis of Aβ, lysates were prepared 
with 8 M urea lysis buffer (8M Urea, 50mM Tris-HCL pH 7.4) freshly 
supplemented with a protease inhibitor cocktail (Sigma-Aldrich) and incubated 
on ice for 30 min. The lysate was mixed with Laemmli sample buffer 
supplemented with beta mercaptoethanol, and equal amounts of protein were 
separated by SDS-PAGE. After transfer onto polyvinylidene difluoride 
membranes (Amersham Hybond P 0.45 PVDF, GE Healthcare Life Science) 
or nitrocellulose membranes (GE Healthcare Life Science), blots were blocked 
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for 1 h with I-BlockTM (Thermo Fisher Scientific) and exposed to 5F4 for 
TREM2 and sTREM2 or 2D8 32 for Aβ. Signals were visualized with 




For in vitro and ex vivo phagocytosis assay the following antibodies were 
used: rat monoclonal antibody 2D8 against Aβ1–16 
32, rabbit polyclonal antibody 
6687 against cytosolic domain of APP 33, mouse IgG2a isotype control 
(Sigma-Aldrich), mouse monoclonal mAb11 (IgG2a; 35,36. mAb11 is a closely 
related clone to the clinically used anti-Aβ antibody Gantenerumab that binds 
preferentially to Aβ 40/42 aggregates, namely Aβ fibrils and oligomers via a 
conformational epitope comprising N-terminal and central epitopes (more 
details on epitopes in 35,36. Affinity parameters were determined before for both 
antibodies by surface plasmon resonance (Biacore) and revealed equilibrium 
dissociation constant (KD) values for mAb11 between 0.14–0.67 nM, which 
were determined for Aβ40 and Aβ42, which is similar to Gantenerumab with a 
KD of 0.6 nM 35,36. Binding and stability of bound antibody to soluble Aβ 
monomers is substantially lower. We measured a KD of 18 nM for 
Gantenerumab binding to Aβ monomers with a notably kinetically instable 
complex with monomers showing a rapid off-rate. In more details, the 
kinetically most stable complex formation with Gantenerumab was observed 
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for Aβ fibrils (kd 2.8×10−4 1/s) and Aβ oligomers (kd 4.9×10−4 1/s), whereas 
for monomeric Aβ a higher dissociation rate was observed (kd 1.2×10−2 1/s) 
suggesting rapid exchange of antibody-bound monomeric Aβ. Thus, mAb11 
binding parameters can be considered almost identical to Gantenerumab. 
Selective binding to aggregated Aβ40/42 is in agreement with demonstrated 
amyloid plaque binding measured by immuno-fluorescence in vitro and in vivo. 
Selective and sensitive binding to amyloid plaques in human AD and 
transgenic mouse brain tissues is again very comparable for Gantenerumab 
and mAb11 with positive immundecoration detectable at low concentration of 
10 ng/mL and plaque binding in vivo in transgenic mice 35,36.  
For immunofluorescence staining of BMDM and primary microglia, 
staining was performed using rat anti-CD68 (1:500; AbD Serotec) and goat 
anti rat Alexa Fluor 555 (1:200; Thermo Fisher Scientific). 
For western blotting of TREM2, we raised a rat monoclonal antibody 
(clone 5F4; 1:50) against the extracellular domain of murine TREM2 (Creative 
Biomart; TREM2-3276M). Further used antibodies were rat antibody 2D8 
(1:100) 32 against Aβ, rabbit-anti calnexin (1:3000; Enzo Life Sciences), 
secondary antibodies HRP-conjugated goat anti-rat (1:5,000; Santa Cruz 
Biotechnology) and goat anti-rabbit IgG (1:10,000; Promega).  
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8. In vitro Aβ phagocytosis assay 
Phagocytosis assays with N9, BMDM and primary microglia were 
performed as described 25 with minor adjustments. Briefly, HiLyte™ Fluor 488 
Aβ1-42 (Anaspec) was aggregated overnight at 37°C with agitation. 3×10
4 N9 
cells, BMDM, or 2×104 primary microglia were plated in poly-D-lysine coated 
black-walled 96 well plates (Greiner bio-one). Pre-aggregated HiLyte™ Fluor 
488 Aβ1-42 (fAβ42) was incubated with antibodies for 1 h at 37°C. Fibril Aβ42 or 
antibody-fAβ42 complexes were added to a final concentration 1 µM and 
incubated for 2 h. As negative control, 10 mM cytochalasin D was added 30 
min before addition of fAβ42 or antibody-fAβ42. Before measurement, medium 
was removed and extracellular fAβ42 was quenched with 100 μl 0.2% trypan 
blue in phosphate buffered saline (PBS), pH 4.4 for 1 min. After aspiration 
fluorescence signals were measured at 485 nm excitation/538 nm emission 
using a Fluoroskan Ascent™ Microplate Fluorometer (Lab Systems).  
For the experiment shown in Fig. 1I, BMDM were incubated with 
recombinant mouse sTREM2 (Creative Biomart) overnight before adding fAβ42 
or antibody-fAβ42 complexes. 
 
9. Ex vivo plaque clearance assay 
Ex vivo plaque clearance assays were performed as previously described 
13 with the following slight modifications. 6-months old APP/PS1 transgenic 
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mice (mixed gender) were perfused with PBS. Brains were separated into two 
hemispheres and snap-frozen using dry ice powder. Frozen brains were 
sectioned into 10 µm sagittal sections using a cryostat (Leica) and collect onto 
poly-D-lysine-coated round glass coverslips (15 mm). Sections were dried at 
room temperature for 2 h followed by incubation with antibodies (isotype 
control (IC) or anti-Aβ) in culture medium for 1 h at 37°C. BMDM or primary 
microglia cells were seeded at densities of 3×105 cells per well in 12 well 
plates and incubated at 37 °C with 5% CO2 for 24 h. After incubation, cultures 
were fixed with 4% paraformaldehyde for 15 min and stained with 
methoxy-X04 (2 µg/ml; Tocris Bioscience). In the indicated experiments, the 
fixed cultures were permeabilized with 0.1% Triton-X100 for 3 min and stained 
with rat anti-CD68 antibody overnight at 4°C followed by methoxy-X04 
staining.  
Images were acquired on a LSM700 confocal microscope with Z stacks 
and tile scan to cover the entire sagittal sections using the Zen 2009 imaging 
software (Zeiss). Maximum intensity projection from each sagittal sections was 
then analyzed by ImageJ 49 to obtain methoxy-x04 signal intensities. In Fig. 4A 
& B, four consecutive slices were set as a group, and signals from slices 
incubated with no cell were set as base line. Methoxy-X04 signal intensities 
from slices either incubated with wt or TREM2 ko BMDM were compared to 
base line. In Fig. 5 A & B eight consecutive slices (#1 - 8) were used as a 
group and signal intensities from slices #1 and 8 were set as base line. Signals 
from slices #2 to 6, which were incubated with increasing concentrations of 
mAb11 (0 – 5 µg/ml) in the presence of BMDM were compared to base line.  
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10. Quantitative real-time PCR analysis 
Total RNA was isolated from BMDM using the RNeasy Mini Kit (Qiagen) 
according the manufacturer’s instructions. The concentration and purity of 
RNA was determined using the NanoPhotomer (Implen). Equal amounts of 
RNA were reverse transcribed into cDNA using High-capacity cDNA Reverse 
Transcription kit (Thermo Fisher). The expression level of Fcγ-receptors (I, IIB, 
III, IV) were analyzed by Taqman® real-time PCR assay. Probes target to 
FcγRI (Mm00438874_m1, Thermo Fisher Scientific), or FcγRIIB 
(Mm00438875_m1, Thermo Fisher Scientific), or FcγIIIR (Mm00438882_m1, 
Thermo Fisher Scientific), or FcγRIV (Mm00519988_m1, Thermo Fisher 
Scientific) were mixed with 1:5 diluted cDNA, added to the Taqman® master 
mix (Thermo Fisher Scientific) and amplified with the 7500 fast real-time PCR 
system (Applied Biosystems). Geometric mean of two housekeeping genes, 
Gusb (Mm01197698_m1, Thermo Fisher Scientific) and Hsp90ab1 
(Mm00833431_g1, Thermo Fisher Scientific), which highly correlate with each 
other, were used as endogenous controls. Fold change of mRNA in TREM2 ko 
BMDM was calculated using wt BMDM as reference sample. 
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11. Statistics 
All statistical analysis were performed using Prism 6 (GraphPad). Data 
are presented as mean +/- SEM with biological repeats. Data from the 
phagocytosis assays were analyzed by 2 way ANOVA with Bonferroni 
correction for multiple comparison. Cell surface FcγR relative levels were 
analyzed by student t-test. Fold change of mRNA was analyzed by one sample 
t-test of its log2 value. Western blot quantification in Fig 2C was analyzed by 2 
way ANOVA with Bonferroni correction for multiple comparison. Methoxy-X04 
signal intensity presented in Fig 4B and Fig 5B were analyzed by 2 way 
ANOVA, with Tukey’s and Fisher's least significant difference (LSD) post-hoc 
tests for pair-wise comparisons respectively. All tests were 2-tailed, with a 
significant level of <=0.05.  
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Figure legends 
Fig. 1 TREM2-deficiency reduces efficacy of antibody-stimulated 
Aββ uptake by phagocytic cells.  
(A) Schematic of the mouse TREM2 locus and the TREM2 protein. 
Sequence alignment of wild-type N9 (N9 wt) and TREM2 mutant N9 (N9 mu) 
surrounding the gRNA target site. The gRNA sequence is in cyan and 
protospacer‐adjacent motif (PAM) is marked with a line. The single nucleotide 
insertion is labeled in red. Schematic representation of wild-type TREM2 
(NP_112544.1) and CRISPR/Cas9 modified TREM2 (N9 mu). TM, 
trans-membrane domain; SP, signal peptide. 
(B) Westernblot analysis of lysates and media from wt and mutant N9 
cells (N9 wt /mu) using antibody anti-murine TREM2 (clone 5F4), which is 
raised against the murine TREM2 extracellular domain. sTREM2, soluble 
TREM2 
* Indicate unspecific bands. Anti-calnexin antibody was used as loading 
control.  
(C) Phagocytosis of 1 µM HiLyte™ Fluor 488 Aβ1-42 (fAβ42) by N9 wt and 
N9 mu in the presence or absence of antibody 2D8 or the non-binding antibody 
6687. Cytochalasin D (CytoD, 10 mM) was used as control to verify phagocytic 
uptake. (n = 4, +/- SEM; 2-way ANOVA, interaction P=0.61, genotype 
P<0.0001, treatment P=0.0001; post hoc tests wt vs. mu for the following 
conditions: fAβ42 P=0.0043, fAβ42-2D8 P=0.0436). 
(D) Westernblot of BMDM derived from wt and TREM2 knockout (ko) 
animals using antibody 5F4. 
(E) Phagocytosis of fAβ42 by BMDM from wt and TREM2
 ko animals in the 
presence or absence of 2D8, or the non-binding control antibody 6687. (n = 3, 
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+/- SEM; 2 way ANOVA, interaction P=0.0005, genotype P<0.0001, treatment 
P<0.0001; post hoc tests wt vs. ko for the following conditions: fAβ42 P=0.0021, 
fAβ42-2D8 1 μg/ml P<0.0001, fAβ42-2D8 5 μg/ml P<0.0001, fAβ42-2D8 10 μg/ml 
P<0.0001, fAβ42/6687 10 μg/ml P=0.0007) 
(F) Quantification of relative fAβ42 uptake to lowest antibody concentration 
used.  
(G) Phagocytosis of fAβ42 by BMDM from wt and TREM2
 ko animals in the 
presence or absence of mAb11, or an isotype control antibody (IC). (n = 4, +/- 
SEM; 2 way ANOVA, interaction P=0.0223, genotype P<0.0001, treatment 
P<0.0001; post hoc tests wt vs. ko for the following conditions: fAβ42-mAb11 1 
μg/ml P=0.0391, fAβ42-mAb11 5 μg/ml P=0.0069, fAβ42-mAb11 10 μg/ml 
P<0.0001, fAβ42-mAb11 20 μg/ml P=0.0001, fAβ42-mAb11 50 μg/ml 
P<0.0001). 
(H) Quantification of relative fAβ42 uptake to lowest antibody concentration 
used.  
(I) Recombinant mouse sTREM2 does not rescue fAβ42 uptake in 
TREM2-deficient BMDM. Increasing amounts of sTREM2 were added to the 
media of wt or TREM2 ko BMDM in the presence or absence of mAb11 (10 
μg/ml).  
(J) Westernblot of primary microglia from wt or TREM2 ko animals using 
antibody 5F4.  
(K) Phagocytosis of fAβ42 by primary microglia from wt and TREM2 ko
 
animals in the presence or absence of mAb11, or an isotype control antibody 
(IC). (n = 5, +/- SEM; 2 way ANOVA, interaction P=0.4797, genotype 
P<0.0001, treatment P<0.0001; post hoc tests wt vs. ko for the following 
conditions: fAβ42-mAb11 5 μg/ml P=0.0449, fAβ42-mAb11 10 μg/ml P=0.0370, 
fAβ42-mAb11 20 μg/ml P=0.0299, fAβ42-mAb11 50 μg/ml P=0.0120). 
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(L) Quantification of relative fAβ42 uptake to lowest antibody concentration 
used.  
(C, E, G, K) Quantification of internalized fAβ42 was normalized to wt 
without antibody. Bonferroni-corrected pair-wise post hoc tests were used.  
 
Fig. 2 Increased Fcγ-receptors expression and enhanced Syk 
phosphorylation in TREM2-deficient BMDM 
(A) Representative histograms for Fcγ-receptors-PE (FcγR-PE) 
expression levels as used for quantification. Stacked histograms for log PE 
fluorescence intensity of wt and TREM2 ko BMDM are shown for the 
respective FcγR (I, IIB/III and IV). 
(B) Relative quantification of cell surface levels of FcγR molecules. 
Absolute number of cell surface FcγR-PE molecules was determined by the 
BD QuantiBRITE® method (see methods section for details) and normalized to 
expression levels of the respective wt control. (n=4, +/- SEM, t test, two-tailed; 
wt vs. ko: FcγRI-PE P=0.0008, FcγRIIB/III-PE P=0.0033, FcγRIV-PE 
P=0.7001). 
(C) mRNA levels of FcγR are increased in TREM2 ko BMDM. Fold 
changes of the respective FcγR (I, IIB, III, IV) mRNA levels in TREM2 ko 
BMDM were determined by quantitative real-time PCR. (n=6, +/- SEM; 
one-sample t test, two-tailed; wt vs. ko: FcγRI P=0.0118, FcγRIIB P=0.0006, 
FcγRIII P=0.0004, FcγRIV P=0.0284) 
(D) Phosphorylated Syk (P-Syk) and total Syk (T-Syk) levels were 
determined by western blotting in lysates from wt and TREM2 ko BMDM after 1 
h treatment with Aβ alone, together with antibody 2D8 (Aβ-2D8), or an isotype 
control (Aβ-IC). Actin was used as a loading control.  
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 (E) Quantification of P-Syk normalized to T-Syk. (n = 4, +/- SEM; 2-way 
ANOVA, interaction P=0.0490, genotype P=0.0898, treatment P<0.0001. 
Bonferroni-corrected pair-wise post hoc tests, ** P =0.0075 vs. wt).  
 
Fig. 3 Engulfment of fibrillar Aβ by BMDM and primary microglia 
(A) A schematic show 10 µm cryosections of unfixed brain cryosections 
from 6-months old APP/PS1 mice, which show a high amyloid plaque burden 
(right panel with methoxy-X04 staining), were incubated with antibody for 1 h, 
followed by adding BMDM or primary microglia on top of the sections. After 24 
h incubation, sections were analyzed by immunostaining or immunobloting.  
(B) mAb11 but not the IC co-localized with methoxy-X04.  
BMDM (C) or primary microglia (D) were cultured on cryosections 
pre-incubated with mAb11 (1 µg/ml). After 24 h, sections were processed for 
immunostaining using antibody against CD68 to identify myeloid cells and 
methoxy-X04 staining to visualize Aβ. Note that both cell types internalize Aβ 
into intracellular vesicles (right panels show enlargement of insets). Scale bar: 
10µm. 
 
Fig. 4 TREM2-deficiency reduces antibody-mediated amyloid plaque 
clearance 
(A) BMDM from wt or TREM2 ko mice were cultured on APP/PS1 mice 
brain cryosections incubated with or without mAb11 (1 µg/ml) or an isotype 
control (IC; 1 µg/ml) for 24 h. Sections were then probed with methoxy-X04. 
Scale bar, 500 µm.  
(B) The amyloid plaque load was quantified from the entire sagittal section. 
Sections incubated with medium (no cell) were set as baseline. (n = 6, +/- SEM; 
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2 way ANOVA, interaction P<0.0001, genotype P<0.0001, treatment P<0.0001; 
Tukey’s multiple comparisons tests; wt vs. ko for the following conditions: no 
antibody P=0.0304, IC P=0.0049, mAb11 P=0.0212; wt : IC vs. wt : mAb11 
P=0.0008; ko : IC vs. ko : mAb11 P=0.0001).  
(C, D) Equal numbers of wt and TREM2 ko BMDM were added and cell 
numbers were analyzed after termination of experiments by quantifying the 
CD68 positive cells on top of the sections. (n = 4, +/-SEM; t-test; n.s., 
nonsignificant, P=0.5004). Scale bar, 200 µm.  
(E) Aβ was extracted by urea buffer from replicate slices of the experiment 
shown in (A) and total Aβ was identified by western blotting.  
 
Fig. 5 Compensation of reduced amyloid plaque clearance by 
elevated antibody dose  
(A) Cryosections from unfixed brain of 6-months old APP/PS1 mice were 
pre-incubated with increasing concentrations of mAb11 (0.001, 0.01, 0.1, 1, 5 
µg/ml).  BMDM from wt or TREM2 ko mice were added for 24 h. Sections 
were stained with methoxy-X04. Scale bar, 500 µm.  
(B) Methoxy-X04 signals were quantified from the entire sagittal section. 
(n = 5, +/- SEM; 2 way ANOVA, interaction P=0.0082, genotype P<0.0001, 
treatment P<0.0001. Fisher’s LSD post hoc comparisons; * show statistics 
between wt and ko under the same experimental condition. # in black show wt 
compares to no antibody stimulation; # in grey show ko compares to no 
antibody stimulation; wt vs. ko for the following conditions: no antibody 
P=0.0053, mAb11 0.001 μg/ml P=0.0003, mAb11 0.01 μg/ml P<0.0001, 
mAb11 0.1 μg/ml P=0.0001, mAb11 1 μg/ml P=0.0007, mAb11 5 μg/ml 
P=0.0011; Following conditions compare to wt / no antibody: wt / mAb11 0.01 
μg/ml P=0.0166, wt / mAb11 0.1 μg/ml P=0.0002, wt / mAb11 1 μg/ml 
P<0.0001, wt / mAb11 5 μg/ml P<0.0001; Following conditions compare to ko / 
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no antibody: ko / mAb11 0.1 μg/ml P=0.0099, ko / mAb11 1 μg/ml P<0.0001, 
ko / mAb11 5 μg/ml P<0.0001.  
 
Expanded View Figure legends 
Fig. EV1 BMDM and primary microglia are positive for CD11b 
Surface staining of CD11b was analyzed using flow cytometry. (A) 97.1% 
bone marrow derived macrophages (BMDM) were positive for CD11b. (B) 
Primary microglia from mixed glial culture were 90.4% positive for CD11b.   
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Expanded View Figure 1 
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Paper II: The TREM2 R47H Alzheimer's risk variant 
impairs splicing and reduces TREM2 mRNA and 
protein in mice but not in humans (Molecular 
neurodegeneration 2018) 
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Abstract  
Background: The R47H variant of the Triggering Receptor Expressed on 
Myeloid cells 2 (TREM2) significantly increases the risk for late onset 
Alzheimer’s disease. Mouse models accurately reproducing phenotypes 
observed in Alzheimer' disease patients carrying the R47H coding variant are 
required to understand the TREM2 related dysfunctions responsible for the 
enhanced risk for late onset Alzheimer's disease.  
Methods: A CRISPR/Cas9-assisted gene targeting strategy was used to 
generate TREM2 R47H knock-in mice. TREM2 mRNA and protein levels as 
well as TREM2 splicing patterns were assessed in these mice, in iPSC derived 
human microglia-like cells, and in human brains from Alzheimer's patients 
carrying the TREM2 R47H risk factor.  
Results: Two independent TREM2 R47H knock-in mouse models show 
reduced TREM2 mRNA and protein production. In both mouse models TREM2 
haploinsufficiency was due to atypical splicing of mouse TREM2 R47H, which 
introduced a premature stop codon. Cellular splicing assays using minigene 
constructs demonstrate that the R47H variant induced abnormal splicing only 
occurs in mice but not in humans. TREM2 mRNA levels and splicing patterns 
were both normal in iPSC induced human microglia-like cells and patient 
brains with the TREM2 R47H variant.   
Conclusions: The TREM2 R47H variant activates a cryptic splice site 
that generates miss-spliced transcripts leading to TREM2 haploisufficiency 
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only in mice but not in humans. Since TREM2 R47H related phenotypes are 
mouse specific and do not occur in humans, humanized TREM2 R47H 
knock-in mice should be generated to study the cellular consequences caused 
by the human TREM2 R47H coding variant. Currently described phenotypes of 
TREM2 R47H knock-in mice can therefore not be translated to humans. 
Keywords: Alzheimer’s disease; microglia; neurodegeneration; TREM2; 
pre-mRNA splicing; human microglia 
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Background 
Microgliosis has long been thought to play a central role in the initiation 
and progression of Alzheimer's disease (AD) pathology. Indeed, genetic 
analyses recently revealed risk variants in a number of genes exclusively or at 
least preferentially expressed in microglia 1–5. Among these, the gene 
encoding the triggering receptor expressed on myeloid cells 2 (TREM2) plays 
a pivotal role in regulating microglial activity 6–9. As part of the disease 
associated signature of microglia (DAM; also called MGnD (microglia 
neurodegenerative disease)), TREM2 is one of the most upregulated genes 
when microglia encounter acute injuries within the brain or respond to 
neurodegenerative disorders such as AD and amyotrophic lateral sclerosis 6,10. 
Moreover, absence of functional TREM2 caused by a gene knockout or certain 
disease associated sequence variants, which missfold TREM2 and retain the 
protein within the endoplasmic reticulum, lock microglia in a homeostatic state 
and prevent their activation in vivo 7,11. As a consequence cellular defense 
mechanisms such as chemotaxis, prominently visible by the lack of clustering 
around amyloid plaques, proliferation, phagocytosis of dead cells and amyloid 
fibrils are all reduced 8,12,13. Furthermore, overexpression of wt human TREM2 
in a TREM2 knockout mouse corrects loss-of-function phenotypes 14. Thus 
TREM2 is believed to have protective functions. In line with that, TREM2 is 
upregulated early during disease development. In a study on patients with 
dominantly inherited AD (DIAN), soluble TREM2 was found to be increased 
five years before onset of clinical symptoms, which may also be interpreted as 
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a protective response 15. Consistent with this conclusion, lack of functional 
TREM2 affects amyloid plaque morphology and increases plaque associated 
neuritic dystrophies 13,16. Furthermore, in models of acute neuronal injury such 
as the cuprizone model, TREM2 activity facilitates clearance of cellular debris 
and recovery 11,17,18. For tauopathies there are, however, opposing results 
indicating either protective or detrimental functions 19,20. In line with findings in 
mouse models for AD pathology, this may be due to stage specific functions of 
TREM2.  
Mouse models and cellular systems greatly helped to understand the 
consequences of loss-of-function mutations / haploinsufficiency of TREM2. 
However, the most important disease variant, namely R47H, which has been 
shown to increase the risk for late onset AD to a similar extent as the Apo 
lipoprotein E (ApoE) ε4 allele 3,4, has been much less investigated. In cultured 
cells TREM2 R47H reduces ligand binding 21–23. Consistent with a pivotal role 
in ligand binding, structural analyses revealed that arginine 47 is required to 
stabilize a conformation, which is capable to interact with ligands such as 
ApoE, and phosphatidylserine 24. Furthermore maturation of the R47H variant 
within the secretory pathway may also be delayed 25. In line with these findings, 
expression of human TREM2 R47H in TREM2 knockout mice failed to rescue 
their phenotypes 14. These findings may therefore be indicative for a 
loss-of-function. In fact, very recently CRISPR/Cas9 generated mouse models 
expressing the R47H variant within the endogenous TREM2 mouse locus 
revealed a significant loss-of function 26,27. TREM2 R47H mice exhibited 
reduced TREM2 upregulation in microglia, reduced microgliosis, reduced 
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clustering around amyloid plaques and an overall reduction of TREM2 protein 
26. Haploinsufficiency of TREM2 was confirmed by a significant reduction of 
TREM2 mRNA derived from the mutant allele 26. Thus, heterozygous TREM2 
R47H mice appear to phenocopy a heterozygous knockout of TREM2.   
We also independently generated TREM2 R47H knock-in mice using the 
CRISPR/Cas9 technology and reproduced haploinsufficiency of TREM2 in this 
model. Moreover, we could demonstrate that reduced mRNA stability due to a 
splicing error leads to a severe reduction of TREM2 mRNA. However, aberrant 
splicing was mouse specific and could not be observed in humans. Thus 
phenotypes associated with the R47H variant inserted into the endogenous 
mouse locus may not allow conclusions on the cellular mechanism affected in 
humans.   
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Materials and Methods 
1. Mice 
Animal handling and animal experiments were performed in accordance 
to local animal laws and housed in standard cages in a specific pathogen-free 
facility on a 12-h light/dark cycle with ad libitum access to food and water. 
 Jax TREM2 R47H ki mice were purchased from Jackson laboratory. 
In-house TREM2 R47H mice were generated using CRISPR/Cas9 technology 
in C57BL/6N background. Both strains were housed and bred in the same 
animal facility. To extract bone marrow, mice were first euthanized by CO2 
followed by cervical dislocation. 
 
2. Generation of TREM2 R47H knock-in mice 
TREM2 R47H knock-in mice (R47H ki mice) were generated by 
CRISPR/Cas9-assisted gene targeting in zygotes as described previously 28,29. 
Briefly, pronuclear stage zygotes were obtained by mating C57BL/6N males 
with superovulated C57BL/6N females (Charles River). Embryos were then 
microinjected into the male pronucleus with an injection mix containing 25 
ng/µl Cas9 mRNA, 12.5 ng/µl TREM2-specific sgRNA, and 25 ng/µl 
single-stranded oligodeoxynucleotide (ssODN). Cas9 mRNA was prepared 
from XbaI-linerized pCAG-Cas9v2-162A by in vitro transcription using the 
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mMESSAGE mMACHINE™ T7 ULTRA Transcription Kit (Thermo Fisher 
Scientific, #AM1345) and purified using the MEGAclear™ Transcription 
Clean-Up Kit (Thermo Fisher Scientific, #AM1908). TREM2-specific sgRNA 
(protospacer: GAAGCACTGGGGGAGACGCA) was prepared by IVT from 
pBS-T7-sgTREM2 using the MEGAshortscript™ T7 Transcription Kit (Thermo 
Fisher Scientific, #AM1354) and purified with the MEGAclear™ Transcription 
Clean-Up Kit. The 130nt ssODN targeting molecule ssTREM2 R47H (5’- 
GGGCATGGCCGGCCAGTCCTTGAGGGTGTCATGTACTTATGACGCCTTG
AAGCACTGGGGTCGACACAAAGCCTGGTGTCGGCAGCTGGGTGAGGAG
GGCCCATGCCAGCGTGTGGTGAGCACACACGGT -3’), comprising the G>A 
substitution (underlined) and three additional silent mutations (bold), was 
synthetized by Metabion. After microinjection, zygotes were cultured in KSOM 
medium until they were transferred into pseudopregnant CD-1 foster animals. 
 
3. Off target analysis of TREM2 R47H mice 
To identify putative off target sites of the TREM2-specific sgRNA, the 
online tool CRISPOR (http://crispor.tefor.net/) 30 was used. Predicted sites with 
a CFD score >0.5 and an MIT score >0.6 were chosen for off-target analysis. 
For analysis, genomic DNA of wildtype and heterozygous mutant TREM2 
R47H mice was isolated and the loci were PCR amplified with primers flanking 
the putative cut sites. PCR amplicons were subsequently Sanger sequenced 
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using PCR amplification primers and the traces compared to a reference 
sequence. 
4. Bone marrow derived macrophages culture 
Bone marrow derived macrophages (BMDM) were prepared as previously 
described 31,32. Briefly, the bone marrow cells were flushed out using advanced 
RPMI 1640 (Life Technologies). Cells were differentiated using advanced 
RPMI 1640 supplemented with 2mM L-Glutamine, 10% (v/v) fetal calf serum 
(FCS), 100 U/ml penicillin, 100 µg/ml streptomycin and 50 ng/ml murine 
M-CSF (R&D System) for 7 days in non-cell culture treated dishes. 
 
5. Microglia isolation  
Microglia were isolated as previously described with some modification 33. 
Wild type and TREM2 R47H ki mice were perfused with cold phosphate 
buffered saline (PBS). Whole brain without the cerebellum was cut into small 
pieces and gently homogenized by mechanical dissociation in homogenization 
buffer (HBSS no calcium, no magnesium, with phenol red; 15 mM HEPES, 0.6% 
glucose). Homogenized cell suspensions were passed through a 100 µm cell 
strainer. Cells were pelleted at 300 g for 10 min and the supernatant discarded. 
To remove myelin, the cell pellets were re-suspended in 22% percoll (GE 
Healthcare) and centrifuged for 20 min at 900 g (acceleration 4, deceleration 
0). Microglia were purified from the pellet using MACS CD11b magnetic beads 
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according to manufacturer’s instructions. Briefly, 20 µl CD11b microbeads 
(Miltenyi) were incubated with cell suspension for 15 min. After incubation, 500 
µl MACS buffer were added and cells were passed over a pre-rinsed Miltenyi 
LS column attached to a magnetic field. The column was washed three times 
with 500 µl MACS buffer, removed from the magnetic field and CD11b positive 
cells were washed out in 5 ml of MACS buffer.  
 
6. Cell lysis and immunoblotting 
To detect membrane bound TREM2, membrane fractions were collected 
as previously described 32. Briefly, cells were lysed in hypotonic buffer (100 
mM Tris-HCl, pH 7.4, 1mM EDTA, 1 mM EGTA, pH 7.4) freshly supplemented 
with a protease inhibitors cocktail (Sigma-Aldrich). Membrane fractions were 
pelleted by centrifugation for 45 min at 16,000 g at 4 °C. Membranes were 
lysed in STEN lysis buffer (150 mM NaCl, 50 mM Tris-HCl, pH 7.6, 2 mM 
EDTA, 1% Triton-X 100) on ice for 20 min. Equal amounts of protein were 
mixed with Laemmli sample buffer supplemented with beta mercaptoethanol 
followed by protein separation by SDS-PAGE. Proteins were transferred onto 
polyvinylidene difluoride membranes (Amersham Hybond P 0.45 PVDF, GE 
Healthcare Life Science) and blocked in 10% I-BlockTM (Thermo Fisher 
Scientific) for 1 hour. Monoclonal antibody 5F4 (dilution 1:100) 32 was used to 
detect TREM2. 
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7. iPSC generation 
Ethical permission for this study was obtained from the National Hospital 
for Neurology and Neurosurgery and the Institute of Neurology joint research 
ethics committee (study reference 09/H0716/64). R47H heterozygous 
fibroblasts were acquired with a material transfer agreement between 
University College London and University of California Irvine Alzheimer’s 
Disease Research Center (UCI ADRC; M Blurton-Jones). Fibroblast 
reprogramming was performed by episomal plasmid nucleofection (Lonza) as 
previously described 34, using plasmids obtained from Addgene (#27077, 
#27078 and #27080). Nucleofected cultures were transferred to Essential 8 
medium (Life Technologies) after 7 days in vitro (DIV) and individual colonies 
were picked after 25-30 DIV. All iPSCs were maintained and routinely 
passaged in Essential 8 medium. Karyotype analysis was performed by The 
Doctors Laboratory (London, UK). Control iPSC lines used in this study are as 
follows: CTRL1 (kindly provided by Dr Selina Wray, UCL Institute of 
Neurology); CTRL2 (SBAD03, Stembancc); CTRL3 (SFC840, Stembancc); 
CTRL4 (BIONi010-C, EBiSC). 
 
8. iPSC-derived microglia (iMG) 
Using previously described protocols, iPSC-microglia (iMG) were 
generated 35,36.  
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Day 0: iPSC lines were cultured to 60% confluency in E8 medium on 
vitronectin-coated 6-well plates. Cells were washed with PBS (w/o 
Ca2+/Mg2+), followed by trypLE digestion (1ml/well; 4 min at 37°C). The 
solution was added to 4 volumes of PBS (w/o Ca2+/Mg2+), and triturated to a 
single cell suspension. The suspension was centrifuged for 3 minutes at 300g 
and the cell pellet resuspended in 1 ml EB differentiation medium (Adapted 
from 36; EBdiff; Essential 8, 50ng/ml BMP-4, 50ng/ml VEGF, 20ng/ml SCF, and 
10µM Y-27632). Cells were counted, and resuspended in EBDiff medium to a 
density of 105 cells/ml. To generate embryoid bodies (EBs), 100 µl of the 
suspension was added to 96 well ultra-low attachment round bottom tissue 
culture plates (Corning), centrifuged at 115g for 3 min, and transferred to a 
tissue culture incubator at 37°C with 5% CO2.  
Day 2: 50 µl of EBdiff medium was added to each well.  
Day 3: Dense EBs were formed and collected with a P1000 Gilson pipette 
into a sterile 15 ml tube, and left to settle. The spent EBdiff medium was 
discarded and 10 ml of myeloid differentiation medium (Mdiff; X-VIVO 15 
medium (Lonza), 1X Glutamax (Life Technologies), 100U 
Penicillin/Streptomycin (Life Technologies), 50 μM β-mercaptoethanol (Life 
Technologies), 100 ng/ml MCSF (Peprotech), and 25 ng/ml IL-3 (Cell 
Guidance Systems)) added. Approximately 150 embryoid bodies (1.5 ×96 well 
plates) were transferred to a 175 cm2 flask containing a further 20 ml of Mdiff 
medium. 
 - 100 - 
 
Day 9-11: Mdiff medium (30ml) was added, to avoid acidosis, being 
careful not to disturb the EBs 
Day 26: Cells were collected from the medium for myeloid marker 
analysis. 
Day 33: Once a week, 1/2 of the Mdiff medium/flask containing budded 
myeloid cells was collected through a 40 µm cell strainer (Falcon, Corning), 
replacing the collected medium with fresh Mdiff. The myeloid cell suspension 
was centrifuged for 3 minutes at 300g and the cell pellet resuspended in 1 ml 
microglial differentiation medium (Adapted from 35; MGdiff; DMEM/F12 HEPES 
no phenol red, 2% ITS-G (Life Technologies), 1% N2 supplement (Life 
Technologies), 200 µM monothioglycerol (Sigma), 1X Glutamax, 1X NEAA 
(Life Technologies), 5µg/ml Insulin (Sigma), 100 ng/ml IL34 (Peprotech), 25 
ng/ml MCSF and 5 ng/ml TGFβ1 (Peprotech), filtered through a 0.22 µm 
syringe filter. Cells were counted and plated in MGdiff, and medium replaced 
every 3-4 days. 
Day 46: MGdiff medium was replaced with microglial maturation medium 
(MGmat: MGdiff + 100ng/ml CD200 (Generon), and 100ng/ml CX3CL1 
(Peprotech)) for 4 days to generate iMG. 
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9. Isolation of human blood derived-monocytes 
Monocytes were obtained from blood through centrifugation with 
Histopaque (Sigma) to isolate peripheral blood mononuclear cells followed by 
separation and purification with CD14-conjugated magnetic beads (Miltenyi). 
Peripheral blood monocytes (PBM) were matured into monocyte-derived 
macrophages (hMacs) in X-VIVO 15 medium with 1% Glutamax, 100U 
Penicillin/Streptomycin, and 100ng/ml MCSF for 7 days. 
10. Microglia signature gene array 
A custom gene array based on published microglial expression data 35,37–
39 was used to confirm a microglial signature in our iMG cultures (TaqMan 
Array Plate 32 plus Candidate Endogenous Control Genes; Thermo Fisher 
Scientific). Complementary DNA was generated from iMG, iPSC-derived 
microglial like cells 36, and human monocyte-derived macrophage (hMacs) 
RNA samples using the High-Capacity RNA-cDNA kit (Life Technologies), 
according to the manufacturer’s instructions. Human primary microglia cDNA 
was also analyzed as a control sample (ScienCell). Quantitative PCR were 
conducted on the Mx3000p qPCR system with MxPro qPCR software 
(Stratagene) using TaqMan Gene Expression Mastermix (Thermo Fisher 
Scientific). Heat maps were generated with the gplots 40 and d3heatmap 41 
packages in R. 
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Microglial gene signature primer details: 
Gene name Primer ID 
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11. Immunocytochemistry 
Cells were fixed in 4% PFA/sucrose in PBS for 20 minutes at room 
temperature (RT), quenched with 50 mM NH4Cl in PBS for 10 min at RT, and 
permeabilised with 0.2% Triton X-100 in PBS for 5 min at RT. Blocking was 
performed with 5% normal goat serum (NGS) in PBS for 30 min. Primary 
antibodies were diluted in 5% NGS/PBS and incubated at RT for 2 hours, 
followed by PBS washes and incubation with corresponding secondary 
antibodies for 1 hour at RT in the dark, with gentle rocking. Nuclei were 
counterstained during mounting using Vectorshield with DAPI (4’, 
6-diamidino-2-phenylindol; Vector Labs). Fluorescence microscopy was 
performed on a Zeiss Axioskop 2 microscope and Axiovison software (Zeiss, 
v4.8). Confocal microscopy was performed on a Zeiss LSM 710 confocal 
microscope using Zen software (Zeiss, Version 2012), and all images were 
processed with Image J1.51K (www.imagej.nih.gov/ij). The following 
antibodies were used: mouse anti-CD68 (1:100, DAKO), rabbit-anti-P2YR12 
(1:200, Atlas Antibodies), mouse-anti-β-Actin (1:500, Sigma), mouse-anti-EZR 
(1:250, Atlas Antibodies), goat anti-rabbit Alexafluor488 (1:500, Life 
Technologies), goat-anti-mouse Alexafluor568 (1:500, Life Technologies). 
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12. Cellular splicing assay 
Human and mouse TREM2 genomic fragments encoding exon 1, intron 1, 
exon 2, and a FLAG tag were synthesized by Integrated DNA Technologies. 
The following primer sets were used for vector cloning: EcoRV-Hs TREM2-Fw 
(GGATATCCGGGCAGCGCCTGACATGCCTG) and NotI-Hs TREM2-Rv 
(ATGCGGCCGCTTAGGATTACAAGGATGACGACGATAAG); HindIII-Mm 
TREM2 Fw (CCCAAGCTTGGGGCGCCTACCCTAGTCC) and XohI-Mm 
TREM2-Rv (CCGCTCGAGCGGCTACTTGTCGTCATCG). The amplified 
fragments were digested by EcoRV/NotI or HindIII/XohI and the digested 
fragments were inserted into pcDNA3.1 (+) (Invitrogen). The mutations were 
introduced in the human and mouse minigene using the QuikchangeTM 
site-directed mutagenesis kit (Agilent). The following mutants were generated: 
(1) R47H is the G>A variant alone encoding arginine; 
(2) R47HTCA is corresponding to sequence variants expressed by the 
in-house generated TREM2 R47H ki mice (GA>TC, G>A, G>A; also see Fig. 
4B);  
(3) R47HAA represents the TREM2 R47H ki mice generated by Jackson 
Laboratory (G>A, G>A, C>A; also see Fig. 4B);  
(4) TC are the silent mutations in in-house generated TREM2 R47H ki 
mice (GA>TC)  
(5) AA are the silent mutations in Jax R47H ki mice (G>A, C>A). 
(6) R47HT represents TREM2 R47H ki mice generated by Cheng 
Hathaway et al. 26 
For the cellular splicing assay 8×105 HEK293 cells were seeded in 6-well 
plates with Dulbecco's Modified Eagle Medium (Life Technologies) 
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supplemented with GlutaMAX™, 10% (v/v) FCS, 100 U/ml penicillin, 100 µg/ml 
streptomycin and cultured overnight. Cells were transfected with 3 µg of 
plasmids to express human or mouse TREM2 minigenes using 6 μl 
lipofectamine 2000 according the manufacturer’s instructions (Thermo Fisher 
Scientific). Transfected cells were cultured in normal medium for 48 hours and 
collected for RNA extraction using RNeasy Mini Kit (Qiagen) according the 
manufacturer’s instructions. The RNA was used for Reverse transcription 
polymerase chain reaction (RT-PCR). 
 
13. Reverse transcription polymerase chain reaction 
1 µg of total RNA was transcribed into cDNA using SuperScript IV reverse 
transcriptase and oligo dT (Thermo Fisher Scientific). 2 μl of cDNA was used 
as template and amplified by polymerase chain reaction (PCR) with GoTaq 
DNA polymerase (Promega) according the manufacturer’s instructions. The 
reaction condition and primer sequences are listed in Table 1. The PCR 
products were loaded into 2% agarose gel with GelRedTM (Biotium) for DNA 
visualization.  
Table 1 Primers and PCR conditions used for detecting splice pattern (Forward: Fwd; 
Reverse: Rev). 
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14. Quantitative real-time polymerase chain reaction 
RNeasy Mini Kit (Qiagen) was used for total RNA isolation according the 
manufacturer’s instructions. 1 µg of total RNA was transcribed into cDNA using 
SuperScript IV reverse transcriptase and oligo dT (Thermo Fisher Scientific). 
RNA levels of human and mouse TREM2 and Tyrobp were analyzed by 
Taqman® real-time PCR using the 7500 Fast real-time PCR system (Applied 
Biosystems). For endogenous controls Gusb (Mm01197698_m1, Thermo 
Fisher Scientific) and Hsp90ab1 (Mm00833431_g1, Thermo Fisher Scientific) 
or GUSB (Hs00939627_m1, Thermo Fisher Scientific) and HSPAB1 
(Hs03043878_g1, Thermo Fisher Scientific) were used. Probes that target 
mouse TREM2 and Tyrobp are Mm04209424_g1, Mm04209423_g1, 
Mm01273682_g1, Mm00449152_m1 (Thermo Fisher Scientific). Probes that 
target human TREM2 and TYROBP are Hs01010721_m1, Hs01003899_m1, 
Hs00182426_m1 (Thermo Fisher Scientific). For allele specific mRNA 
expression custom made primers and probes were designed. The primer pair 
for mouse TREM2 is: CCTTGAGGGTGTCATGTACTTAT and 
TCCCATTCCGCTTCTTCAG. The probes for the mouse wild-type allele and 
R47H allele are /5HEX/CCTT+G+C+GT+CT+CC/3IABkFQ/ (+, lock nucleic 
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acid) and /56-FAM/CTT+T+G+T+GT+C+GA+C/3IABkFQ/, respectively 
(Integrated DNA Technologies). The primer pair for human TREM2 is 
ACAAGTTGTGCGTGCTGA and ATGACTCCATGAAGCACTGG. The probes 
for the human wild-type allele and the R47H allele are 
/5HEX/CTT+G+C+GCCT+CC/3IABkFQ/ and 
/56-FAM/TT+G+T+GC+CT+CC/3IABkFQ/, respectively (Integrated DNA 
Technologies). The probes and primers were mixed in 1:2 ratios for 
quantitative PCR reaction.  
cDNAs were diluted 1:5 with H2O and 9 µl of diluted cDNA together with 1 
µl of primer probe mix, 10 μl of Taqman® master mix (Thermo Fisher Scientific) 
were used in one 20μl reaction.  
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Results 
1. Reduced mRNA and protein level in TREM2 R47H 
knock-in mice                                       
The rare TREM2 variant rs75932628-T encodes a histidine instead of 
arginine at position 47 (R47H) and increases the risk for AD around three fold 
3,4. The DNA and amino acid sequence around arginine at position 47 is highly 
conserved across different mammalian species (Fig. 1a & b). To study the 
impact of this variant on TREM2 function in microglia in vivo we generated 
TREM2 R47H knock-in mice (R47H ki mice) by introducing a G>A mutation 
using the CRISPR/Cas9 technology (Fig. 1c). Two silent mutations were 
additionally introduced (GA>TC) to create a SalI restriction site for genotyping 
(Fig. 1c). In addition, a silent G>A mutation was generated to block the 
protospacer-adjacent motif (PAM) to allow higher gene editing efficiency (Fig. 
1c). The predicted potential off-target sites were analyzed. An off-target event 
with a Δ10-Indel mutation was identified at an intragenic region on 
chromosome 11 (Additional file 1: Fig. 1, putative off-target #2). The founder 
mouse was back-crossed to C57BL/6N, and off-spring with positive TREM2 
R47H ki but negative off-target #2 (i.e ID-7-1; ID-7-2; ID-7-4) were used for 
establishing the mouse line. Expression of total TREM2 mRNA as well as both 
TREM2 mRNA transcripts (NM_031254.3 and NM_001272078.1), encoding 
either membrane bound TREM2 or a truncated soluble version was validated 
in brain. Interestingly, total TREM2 mRNA including both TREM2 transcripts 
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was significantly reduced in a gene dose-dependent manner, whereas mRNA 
expression of Tyrobp (NM_011662), the adaptor protein of TREM2 42, 
remained unchanged (Fig. 1d). Using allele specific qPCR we confirmed that 
expression of the R47H allele is selectively reduced compared to the wt allele 
in heterozygous R47H ki mice (Fig. 1e & Additional file 4: Table S1).  
To confirm decreased TREM2 expression on protein level, we purified 
microglia from wild-type (wt), heterozygous (het), and homozygous (hom) 
R47H ki mice and performed western blotting of membrane fractions. 
Membrane-bound TREM2 showed a gene dose-dependent reduction (Fig. 1f).  
Reduced TREM2 R47H mRNA and protein expression was further 
confirmed in bone marrow derived macrophages (BMDM). Consistent with our 
findings in brain and microglia, mRNA of both TREM2 transcripts decreased in 
a gene dose-dependent manner whereas mRNA of Tyrobp remained 
unchanged (Fig. 1g). Furthermore, immature and mature TREM2 as well as 
soluble TREM2 (sTREM2) were also reduced in a gene dose dependent 
manner (Fig. 1h).  
To exclude that reduced TREM2 mRNA and protein expression is 
artificially caused by the introduction of the three silent mutations, we analyzed 
TREM2 R47H knock-in mice generated by Jackson laboratory (Jax R47H ki 
mice). In addition to the target variant R47H, these mice harbor two silent 
mutations (Fig. 2a). One of the silent mutations is a G>A exchange to block the 
PAM sequence exactly like in the mice generated within our laboratory. The 
second silent mutation C>A is only present in the Jax R47H ki mice (Fig. 2a). 
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We investigated TREM2 mRNA and protein levels using homozygous Jax 
R47H ki mice and their wt counterparts. Again, mRNA from total TREM2 as 
well as from both transcripts of TREM2 decreased in brains of homozygous ki 
mice whereas mRNA expression of Tyrobp remained unchanged (Fig. 2b). 
Western blotting of membrane fractions from BMDM from the Jax R47H ki 
mice also confirmed a significant reduction of membrane bound and soluble 
TREM2 (Fig. 2c). Thus reduction of mRNA and protein levels in TREM2 R47H 
ki mouse was confirmed in two independent mouse models. 
 
2. Aberrant splicing of exon1/2 in TREM2 R47H knock-in 
mice  
Next, we searched for the cellular mechanism responsible for the 
substantial reduction of the TREM2 R47H mRNA in the two mouse models. 
Since nonfunctional mRNAs are rapidly removed by mRNA surveillance 
systems 43, we studied splicing of the first intron which separates exon 2 
containing the R47H variant from exon 1 harboring the translation initiation site 
and upstream untranslated sequences. Using RT-PCR with primer pairs 
against the 5’ end of exon 1 and the 3’ end of exon 2, we compared the 
splicing patterns of TREM2 in R47H ki and wt mice (Fig. 3a). A single splicing 
product of the expected length (465 base pairs) was obtained from wt TREM2 
mRNA (Fig. 3b). Surprisingly, an additional smaller splicing product (346 base 
pairs) was observed in TREM2 R47H heterozygous mice, which was even 
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more abundant in TREM2 R47H homozygous mice (Fig. 3b) while at the same 
time the larger splicing product was reduced in a gene dose dependent 
manner (Fig. 3b). This suggests aberrant splicing of TREM2 pre-mRNA 
derived from the mutant allele. To independently confirm aberrant splicing, we 
investigated the Jax R47H ki mice described in Fig. 2. Again, we found an 
additional smaller RT-PCR product in mutant but not wt mice (Fig. 3c). 
Furthermore, the larger splicing product was reduced in homozygous ki mice 
(Fig. 3c). Thus aberrant splicing of R47H pre-mRNA occurs in two independent 
mouse models. DNA sequencing of the splicing products revealed correct 
splicing of exon 1 and exon 2 in wt mice and to a lesser extent also in the ki 
mice (Fig. 3d). However, DNA sequencing of the additional shorter RT-PCR 
product of both mutant mice revealed that 119 base pairs were deleted at the 5’ 
end of exon 2 (Fig. 3d & Additional file 2: Fig. 2). The deletion leads to a frame 
shift and a premature stop codon in exon2 (Fig. 3d), which may lead to 
nonsense mediated mRNA decay and thus explain the consistent reduction of 
the mutant mRNA in both mouse models.  
 
3. The R47H variant does not affect splicing and mRNA 
levels in humans  
To directly compare the splicing pattern of mouse and human TREM2 
R47H, we expressed mouse or human TREM2 minigenes containing exon 1, 
intron 1, and exon2 in human embryonic kidney 293 cells (HEK 293) (Fig. 4a). 
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To separately investigate the disease causing TREM2 R47H variant and the 
silent mutations, we introduced the corresponding sequence variants either 
alone or together (Fig. 4b). Upon expression of the minigene encoding the 
mouse TREM2 sequence, we observed miss-splicing induced by the R47H 
variant alone (R47H) (Fig. 4c). Similar aberrant splicing was observed when 
the two silent mutations of the Jax R47H ki mice were expressed in addition to 
the R47H variant (R47HAA), whereas introduction of the two silent mutations 
alone (AA) did not affect splicing (Fig. 4c). Moreover, when the three silent 
mutations used to generate our in-house mouse model were combined with 
the R47H (R47HTCA), a striking increase of aberrant splicing was observed. 
When we only introduced the unique TC mutations used to generate our 
mouse model (TC) we also observed impaired splicing (Fig. 4c), suggesting 
that R47H and TC together display synergistic effects on aberrant splicing. 
This demonstrates that the R47H variant by itself is sufficient to induce 
aberrant splicing, but enhanced miss-splicing upon the addition of silent 
mutations implies that this genomic region is very sensitive for splicing errors 
induced by minor changes within the pre-mRNA sequence. Finally, we also 
investigated if the mutations introduced into the mouse genome by 
Cheng-hathaway et al. 26 affect pre-mRNA splicing of TREM2. Very similar to 
our R47H ki mice and those generated by the Jackson Laboratories, the 
mutations introduced by Cheng-hathaway and colleagues (R47HT) caused 
aberrant splicing (Fig. 4c), which is consistent with the haploinsuffciency also 
observed in this model 26.  
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To prove if this is also true for human TREM2, we investigated the same 
TREM2 variants in human minigene constructs (Fig. 4a, b & d). Surprisingly, 
our results demonstrate that neither the R47H variant alone or in combination 
with the silent mutations used to generate the ki mouse models affected 
correct exon1/2 splicing (Fig. 4d). This suggests that only the mouse gene 
locus is vulnerable for aberrant splicing upon introduction of these sequence 
variants and implies that the R47H mutation does not affect splicing and 
mRNA levels in humans.  
To provide direct evidence for this prediction, we investigated exon 1/2 
splicing in humanized TREM2 mice generated by ectopic expression of the 
human wt or R47H mutant TREM2 locus in TREM2-/- mice 14. Using the same 
RT-PCR strategy as described above (Fig. 3a), we could only detect the 
correctly spliced exon 1 and 2 but no aberrantly spliced additional products 
(Fig. 5a).  
Similarly, in human induced pluripotent stem cell (iPSC) derived microglia 
(iMG) with the wt TREM2 allele or heterozygous for the TREM2 R47H variant 
(Additional file 3: Fig.3) we also detected only the correctly spliced exon 1 and 
2 (Fig. 5b). Furthermore, no aberrant splicing was detected in AD cases 
carrying one R47H mutant allele (Fig. 5c). Direct sequencing demonstrated 
correct exon1/2 splicing in human iMG and in AD cases. Lack of aberrant 
splicing of human TREM2 R47H is consistent with no reduction of total TREM2 
mRNA in iMG with one R47H allele (Fig. 5d). In addition, using allele specific 
qPCR we confirmed that the expression of the R47H allele is comparable to wt 
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in iMG (Fig. 5e & Additional file 5: Table S2), and in human brain (Fig. 5f & 
Additional file 5: Table S2). Taken together, aberrant splicing of R47H mutant 
pre-mRNA is not observed in humans and consequently no haploinsufficiency 
of TREM2 could be detected.   
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Discussion 
Most functional studies of TREM2 have so far been performed with either 
total loss-of-function models or by studying the TREM2 T66M mutation 7,8,11–
13,19,20,44,45, which is associated with an FTD-like syndrome. Homozygous mice 
expressing the TREM2 T66M variant phenocopy a number of functional 
deficits also observed upon total loss of the TREM2 encoding gene 11. These 
include delayed resolution of inflammation upon lipopolysaccharide stimulation, 
reduced phagocytic activity, reduced microglial activation during physiological 
ageing and neurological insults, reduced cerebral blood flow, reduced cerebral 
brain glucose metabolism, impaired chemotaxis and clustering of microglia 
around amyloid plaques 11. However, much less is known about the functional 
impact of the TREM2 R47H variant, which is associated with a high risk for AD 
similar to that caused by the ApoE ε4 allele 3,4,46. In vitro studies suggested 
reduced binding of Aβ oligomers, ApoE, and phosphatidylserine due to 
structural alterations in TREM2 8,21–24. Furthermore maturation of the R47H 
variant within the secretory pathway may also be delayed 25. Expression of 
human TREM2 R47H in TREM2 knockout mice failed to rescue the knockout 
phenotypes again supporting the notion that TREM2 is protective and that 
TREM2 variants associated with neurodegenerative diseases may cause a 
loss-of-function 14. TREM2 R47H knock-in mice expressing this variant under 
physiological conditions resulted in phenotypes that were compatible with a 
loss-of function 26. Cheng-Hathaway et al. reported that TREM2 R47H 
heterozygous mice showed reduced TREM2 expression in microglia close to 
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amyloid plaques, reduced microglial proliferation, reduced dense core plaques 
and increased neuritic dystrophy 26. These phenotypes were associated with 
reduced TREM2 mRNA expression 26. Similarly, Sudom et al. reported 
reduced TREM2 protein expression in brain as well as reduced sTREM2 in 
plasma from R47H knock-in mice 24. All together, this suggests that the 
AD-associated TREM2 R47H variant is also associated with a loss-of-function. 
However, whereas the T66M mutation causes a loss-of-function due to 
retention of the misfolded mutant protein within the endoplasmatic reticulum 
11,25, the R47H mutation appears to cause haploinsufficiency due to reduced 
mRNA levels 26. We generated a similar mouse model using the 
CRISPR/Cas9 technology. Consistent with published findings, our mouse 
model also showed reduced TREM2 mRNA and protein levels. Furthermore, 
similar findings were made using an independent mouse generated by 
Jackson Laboratories. We therefore searched for a joined cellular mechanism, 
which may be involved in the significant reduction of TREM2 mRNA and 
protein in both mouse models. Surprisingly, we found that the introduction of 
the R47H variant by itself but even more so the introduction of additional silent 
mutations caused aberrant splicing. Direct sequencing of the aberrant splicing 
product revealed that it lacks 119 base pairs. Close inspection of the sequence 
of the alternative splice product revealed that a cryptic splice acceptor site 
within the exon 2 was activated. This leads to the elimination of parts of exon 2 
resulting in a splicing product containing a premature stop codon. It is well 
known that such aberrant mRNAs are rapidly degraded by nonsense-mediated 
mRNA decay 47. Note that the TaqMan probes used for detecting TREM2 
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mRNA were either bound to exon 3/4 or exon 4/5 boundary (Fig. 1d) thus they 
detect both the full length functional TREM2 mRNA and the aberrantly spliced 
shorter variant. Therefore, the apparent degree of reduction for TREM2 mRNA 
and protein is not equal (Fig. 1d & f). In addition however, we cannot fully 
exclude the possibility that the R47H variant may also affect mouse TREM2 
protein stability. 
The mRNA reductions caused by aberrant splicing, which were consistent 
in two independent mouse models, led us to investigate if aberrant exon 2 
splicing in humans also leads to TREM2 haploinsufficiency. We found that 
TREM2 mRNA levels and splicing patterns were both normal in iPSC derived 
human microglia-like cells and in patient brain with the TREM2 R47H variant. 
Furthermore, cellular splicing assays using minigene constructs demonstrate 
that the R47H variant induced abnormal splicing only occurs in mice but not in 
humans. Thus, both the R47H variant as well as additionally introduced silent 
variants cause a mouse specific reduction of the TREM2 mRNA. Therefore, 
these findings cannot be translated to humans calling for novel humanized 
R47H mouse models. 
 
Conclusions 
The AD-associated TREM2 R47H variant in combination with silent 
mutations introduced by the CRISPR/Cas9 technology causes mouse specific 
aberrant splicing of exon 2, which leads to an alternative TREM2 mRNA 
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containing a premature stop codon. The observed significant reduction of 
TREM2 mRNA and protein in R47H ki mice are most likely the consequence of 
nonsense-mediated mRNA decay of the aberrant transcript and it is not 
observed in human systems. Thus, functional data derived from TREM2 R47H 
knock-in mice cannot be translated to humans. 
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Figure legends  
Figure 1 Trem2 mRNA and protein are reduced in a novel Trem2 
R47H knock-in mouse model 
a & b Evolutionary conservation of TREM2 at the DNA (a) and protein (b) 
level. c Strategy to generate Trem2 R47H knock-in (R47H ki) mice indicating 
the protospacer region (green), protospacer adjacent region (PAM, purple), 
and the introduced nucleotide changes (orange or red). The restriction site for 
SalI is underlined. d Trem2 and Tyrobp mRNA levels in brains from R47H ki 
mice. TaqMan probes for the exon 4/5 boundary were used to detect total 
Trem2 mRNA. TaqMan probes for the Trem2 exon 3/4 boundary were used for 
isoform discrimination. (N=3, +/-SEM, one way ANOVA, Bonferroni-corrected 
pair-wise post hoc tests, total Trem2 WT vs. Het P=0.0002, WT vs. Hom 
P<0.0001; Trem2 isoform 1 WT vs. Het P=0.0029, WT vs. Hom P<0.0001; 
Trem2 isoform 2 WT vs. Het P=0.0031, WT vs. Hom P=0.0002. n.s. 
Non-significant.). e Allele specific Trem2 mRNA expression in heterozygous 
R47H ki mice. Customized probes were against Trem2 R47H and its neighbor 
region (see also Materials and Methods). (N=3, +/-SEM, unpaired t test, 
P<0.0001). f Trem2 protein expression in microglia isolated from Trem2 wt or 
R47H ki mice. (N=3,+/-SEM, one way ANOVA, P<0.0001, 
Bonferroni-corrected pair-wise post hoc tests, WT vs. Het P=0.0005, WT vs. 
Hom P<0.0001). g Trem2 and Tyrobp mRNA levels in bone marrow derived 
macrophages (BMDM) isolated from Trem2 wt and R47H ki mice. (N=3, 
+/-SEM, one way ANOVA, Bonferroni-corrected pair-wise post hoc tests, 
 - 126 - 
 
Trem2 WT vs. Het P=0.0002, WT vs. Hom P<0.0001; Trem2 isoform 1 WT vs. 
Het P<0.0001, WT vs. Hom P<0.0001; Trem2 isoform 2 WT vs. Het P=0.0008, 
WT vs. Hom P<0.0001. n.s. Non-significant.) h Expression levels of membrane 
bound and soluble Trem2 (sTrem2) protein in bone marrow derived 
macrophages (BMDM) isolated from Trem2 wt or R47H ki mice. (N=3, +/-SEM, 
one way ANOVA, Trem2 P=0.0003, Bonferroni-corrected pair-wise post hoc 
tests, WT vs. Het P=0.0026, WT vs. Hom P=0.0002, sTrem2 P=0.0007, WT vs. 
Het P=0.0469, WT vs. Hom P=0.0005). 
 
Figure 2 Trem2 haploinsufficiency in an independent R47H knock-in 
mouse model provided by Jackson laboratories  
a DNA sequence comparison of in-house made Trem2 R47H ki mice 
(R47H ki mice) and Jax Trem2 R47H ki mice (Jax R47H ki mice). b Trem2 and 
Tyrobp mRNA levels in brains of wt or Jax R47H ki mice. (N=3, +/-SEM, 
unpaired t test, Trem2 isoform1 P=0.0002; Trem2 isoform2 P=0.0001. n.s. 
Non-significant.). c Expression levels of membrane bound and soluble Trem2 
(sTrem2) protein in bone marrow derived macrophages (BMDM) isolated from 
Trem2 wt or Jax R47H ki mice (N=3, +/-SEM, unpaired t test, Trem2 P=0.0016, 
sTrem2 P=0.0433) 
 
Figure 3 Aberrant splicing of exon1/2 in two independent Trem2 
R47H knock-in mice 
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a Schematic representation of exon/intron boundaries of Trem2 and the 
strategy used to investigate exon 1/2 splicing. b RT-PCR mediated 
amplification of splicing products generated by R47H ki mice. c RT-PCR 
mediated amplification of splicing products generated by Jax R47H ki mice. d 
DNA and amino acid sequence of the two splice products identified.  
 
Figure 4 Aberrant splicing of Trem2 variants containing the R47H 
mutation with and without additional mutations used to create three 
different R47H ki mice  
a The minigene construct used to investigate exon1/2 splicing of the 
Trem2 variants shown in (b). b Sequence alignment of Trem2 variants 
investigated for aberrant splicing. c Exon 1/2 splicing of mouse Trem2 variants 
described in (b). d Exon 1/2 splicing of human TREM2 variants described in 
(b). Note that only mouse transcripts undergo aberrant splicing. EV: empty 
vector.  
  
Figure 5 Normal exon 1/2 splicing of human TREM2 pre-mRNA 
encoding the R47H variant 
a Normal splicing of human TREM2 upon ectopic expression of the 
human wt or R47H mutant TREM2 locus in Trem2-/- mice. b Normal exon 1/2 
splicing of Trem2 in human induced pluripotent stem cell (iPSC) derived 
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microglia (iMG) with the wt TREM2 allele or heterozygous for the TREM2 
R47H variant. c No aberrant splicing of the R47H variant in an AD case 
carrying one R47H mutant allele. d No reduction of total TREM2 mRNA in iMG 
with one R47H allele. (N=4, +/-SEM, unpaired t test, non-significant.) e Allele 
specific qPCR demonstrates that the expression of the R47H allele is 
comparable to the wt allele in iMG. (N=7, +/-SEM) f Allele specific qPCR 
demonstrates that the expression of the R47H allele is comparable to wt allele 
in human brain derived from a R47H carrier. (N=2). Customized probes were 
against Trem2 R47H and its neighbor region (see also Materials and 
Methods). 
 
Additional file 1: Figure 1 Off-target analysis of in-house made Trem2 
R47H knock-in mice 
a Sanger-sequencing chromatogram of the Trem2 on-target site and the 
six putative off target sites of animal Trem2 R47H ki ID-7. Mixed peaks in the 
Trem2 locus show the correct R47H substitution (CGC>CAC) and the three 
silent mutations for genotyping purposes. Mixed peaks in traces of site #2 
reveal a Δ10-Indel mutation at the putative cut site, indicating a true off target 
event. Underlined: Protospacer; arrow head: putative cut site; green letters: 
PAM site on shown strand; red letters: PAM site on complementary strand; 
yellow: Δ10-Indel mutation. b Sanger sequencing results of Trem2 R47H 
positive off-springs of male ID-7, which was crossed with a C57BL/6N female. 
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The Δ10-Indel allele was inherited to animals ID-7-3 und ID-7-12 that were 
excluded from any further breedings and experiments. 
 
Additional file 2: Figure 2 Sequence of the aberrantly spliced murine 
Trem2 mRNA 
 Trem2 gene sequence. Exon in black; intron in green; // indicates splicing 
sites. 
 
Additional file 3: Figure 3 iMG differentiation and validation 
a Schematic of the in vitro differentiation of iPSC-derived microglia (iMG). 
(i): Human iPSCs are grown in feeder free conditions with no spontaneous 
differentiation. Scale bar: 250 µm. (ii): Embryoid bodies are formed in the 
presence of 3 factors SCF, BMP4, and VEGF; Scale bar: 750 µm. (iii): Myeloid 
cells are generated after culturing with IL3 and MCSF growth factors for 3-4 
weeks, then stained for classic myeloid/macrophage markers CD68. Scale bar: 
50 µm. (iv): Further differentiation to microglia-like cells that positive for 
microglial markers P2RY12. Scale bar: 20 µm. (v): Addition of the two final 
factors (CD200 and CX3CL1) matures the iMG. Scale bar: 20 µm. b Heat map 
showing mRNA expression of a microglial gene signature in iMG, human 
monocyte-derived macrophages (hMac), human primary microglia (hMG), and 
iPSC samples. Clear clustering is observed between iMG and hMG. 
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Additional files 4: Table S1 Allele specific quantitative PCR for Trem2 
R47H knock-in mice 
 
Additional files 5: Table S2 Allele specific quantitative PCR for iMG 
and patient brains  
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Summary and general Discussion 
TREM2 contributes to antibody-mediated uptake 
My findings indicate that TREM2 deficiency impairs anti-Aβ 
antibody-mediated amyloid clearance. In line with the well described 
phagocytic defects in TREM2 ko cells 1–6, showed that microglia and 
macrophages lacking functional TREM2 engulf less fibrillar Aβ. This is in 
contrast to some studies that show wt and TREM2-deficient microglia engulfed 
similar amount of Aβ fibrils in in vitro assay 7,8. The discrepancy may be 
explained by differences of Aβ fibril preparation and/or differences in microglia 
preparation and cultivation conditions. One of the limitations of in vitro 
phagocytosis assays is the use of synthetic Aβ fibrils for phagocytosis, which 
may not represent amyloid plaque clearance. With this limitation in mind, I 
used an ex vivo slice assay to monitor the clearance of physiologically-formed 
amyloid plaques. Microglia with or without functional TREM2 were cultured on 
top of consecutive cryosection slices from aged APP/PS1 mice with amyloid 
plaque pathology. In line with the phagocytosis of fibrillar Aβ, TREM2-deficient 
microglia clear fewer physiologically-formed amyloid plaques. This finding 
suggests that TREM2 loss-of-function reduces amyloid plaque clearance. This 
clearance defect suggests that TREM2 regulates Aβ phagocytosis as well as 
Aβ degradation, which is supported by the finding that TREM2 regulates the 
degradation of Aβ oligomers 7. The reduced plaque clearance capacity in 
microglia lacking functional TREM2 is further supported by the recent finding 
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that TREM2-dependent activity may promote Aβ clearance to limit the growth 
of newly seeded plaques 9. In vivo TREM2-dependent activities include many 
aspects of microglial functions, for example, phagocytosis, migration, 
proliferation and ApoE-secretion. TREM2 deficiency impairs microglial survival 
in mice with AD pathology 8. In the ex vivo slice assay, cell survival was 
controlled by measuring cell density before and after incubation. No cell death 
was detected during the incubation period. This may be due to the short 
incubation period or to the fact that the cells were in an activated stage since 
they were in close contact with brain slices. TREM2 deficiency also reduces 
microglial migration towards stumuli 10. This migration defect might contribute 
to the observed reduction in plaque clearance in TREM2 loss-of-function cells; 
therefore, a high density of microglia was used in this study to limit the 
migration requirements.  
To study the anti-Aβ antibody-mediated uptake, Anti-Aβ antibody mAb11 
was used to mimic the clinical situation as the binding properties of mAb11 is 
similar to the clinically used gantenerumab 11,12. mAb11 strongly boosted Aβ 
and amyloid plaque engulfment in a concentration-dependent manner in the 
presence or absence of functional TREM2. However, TREM2-deficiency 
significantly reduced the uptake of antibody-bound fibrillar Aβ and the 
clearance of antibody-covered plaques in all conditions tested, indicating that 
the phagocytic machinery is impaired. Surprisingly, the fold increase of uptake 
in response to increasing antibody concentration was similar between TREM2 
ko phagocytes and their wt counterpart. This indicates that although the 
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TREM2-dependent machinery is impaired, a TREM2-independent pathway 
might contribute to the antibody-mediated uptake.  
The uptake of antibody-bound immune complexes are mainly mediated by 
the Fc gamma receptors (FcγR) 13,14. FcγR mediated pathway might 
compensate the phagocytic defects in TREM2 deficient cells. The mRNA level 
of the main Fc gamma receptors, FcγRI, FcγRIIB, FcγRIII and FcγRIV, were 
increased in macrophages from TREM2 deficient animals, and this mRNA 
upregulation is translated into increased cell surface protein expression of 
FcγRI, FcγRIIB, FcγRIII. The functional consequence of the increased cell 
surface FcγRs was that the phosphorylation of Syk, the common downstream 
signal for TREM2 and FcγR activation 15–17, was much stronger in 
TREM2-deficient cells upon Aβ-antibody complex stimulation. This 
demonstrates that increased cell surface FcγRs induced stronger downstream 
signaling. Furthermore, the increased FcγRs signaling might compensate for 
the TREM2-dependent phagocytic defects, explaining why antibody treatment 
can promote Aβ and amyloid plaque clearance in a concentration-dependent 
manner in the absence of functional TREM2. In addition to phagocytosis, 
activation of FcγRs results in pro-inflammatory response including the release 
of TNFα and IL-1β, which may negatively affect neurons 18,19. Therefore, the 
observed increase in FcγRs activation in TREM2 loss-of-function microglia 
may lead to stronger antibody-induced side effects. To finally address this 
question, it will be important to study TREM2-dependent antibody effector 
functions in vivo. 
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Antibody-mediated amyloid plaque clearance is normally time- and 
dose-dependent 11,20. Titration experiments were used to study the efficacy of 
antibody-mediated uptake. An obvious concentration-dependent clearance 
was observed in both genotypes. Again, at all conditions used, 
TREM2-deficient macrophages cleared less amyloid deposits. The ex vivo 
assay indicates that TREM2-deficiency impairs the amyloid clearance capacity; 
however, it can be promoted with increasing antibody concentration due to the 
enhanced FcγR signaling.  
A limitation of my study is that it is lacking in vivo validation. In future in 
vivo studies, the experimental subjects should be carefully chosen (e.g. age 
and models), since the impact of TREM2 on plaque load is biphasic, with 
attenuation of plaque growth at the early but not late stage 9. Most mouse 
models with plaque pathology have strong overexpression of APP and PS1 
with disease-causing mutations, and this may easily override the modulation 
effects mediated by TREM2. 
The in vitro and ex vivo assays are controlled systems that were used for 
investigation of TREM2-dependent antibody-mediated phagocytosis. Thus, my 
finding that the phagocytic deficiency is partially compensated for by enhanced 
FcγRs signaling in TREM2 loss-of-functions microglia is relevant for clinical 
studies as microglia-mediated plaque clearance is important for the outcome 
of amyloid-based AD therapies. My data also suggest that higher antibody 
dosage should be considered in TREM2 deficient patients. TREM2-dependent 
phagocytosis is important for both amyloid and antibody-bound amyloid 
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clearance, and thus microglia activation via TREM2-modulation may boost 
amyloid clearance to achieve optimal therapeutic outcome. 
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The TREM2 R47H variant impairs TREM2 splicing in 
mice but not in humans 
The TREM2 R47H variant, encoded by rs75932628-T, is one of the 
strongest risk factors for LOAD 21,22. Studies utilizing TREM2-deficient mice 
and cells reveal that TREM2 is crucial for microglial functions, for example, 
microglia activation during normal aging, phagocytosis of cellular debris and 
protein aggregates, and migration 1,3,23–25. In vitro studies indicate that the 
R47H variant impairs TREM2 binding to lipids, ApoE and Aβ oligomers 7,8,26,27, 
suggesting that the R47H variant weakens TREM2 functions. In addition, 
structural analysis of TREM2 shows that R47 is important for structure 
stabilization of TREM2 28. However, it is unclear how the R47H variant 
modulates disease progression in vivo. Overexpression of human TREM2 
R47H in TREM2-/- : 5×FAD mice failed to rescue TREM2 loss-of-function 
phenotypes, including reduced microgliosis and microglia activation 29. This 
data suggests that the AD-associated variant R47H causes loss-of-function 
phenotypes and that TREM2 is protective against disease progression. The 
potential functions of sTREM2 might also be impaired by the R47H mutation. 
sTREM2 binds to neurons and amyloid plaques, and the R47H variant impairs 
this binding 29. Consistent with the loss-of-function hypothesis, Parhizkar and 
colleagues reported that microgliosis and plaque-associated ApoE both are 
reduced in AD patients with the TREM2 R47H variant 9. A very recent study 
using TREM2 R47H ki mouse model with endogenous TREM2 expression 
shows that the TREM2 R47H heterozygous mice exhibited reduced plaque 
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associated microglia, reduced proliferation and increased plaque-associated 
neuritic dystrophy 30. The R47H variant reduces the TREM2 mRNA level, and 
this was thought to be the reason for the TREM2 loss-of-function phenotypes, 
at least in mice 30.  
Together with B. Wefer, I also independently generated TREM2 R47H ki 
mice (R47H ki mice) using the CRISPR/Cas9 technology. Of note, all the 
available TREM2 R47H ki mice, including the one generated in-house, the one 
reported by Cheng-Hathaway et al 30 and the one generated by Jackson 
laboratory (Jax R47H mice), harbor the R47H mutation as well as silent 
mutations facilitating genome editing. In line with the published findings 30, 
TREM2 mRNA and protein were reduced in the in-house R47H ki mice in a 
dose-dependent manner. Furthermore, TREM2 mRNA and protein are also 
decreased in Jax R47H mice. The observed TREM2 mRNA and protein 
reduction from three different TREM2 R47H ki mice is most likely caused by 
the R47H variant. 
It is known that the quality of mRNA is tightly controlled by mRNA 
surveillance systems 31. Surprisingly, an aberrant splicing was detected in two 
TREM2 R47H ki mouse models (in-house generated R47H ki mice and Jax 
R47H mice). A cryptic acceptor site within the exon 2 was activated, leading to 
a deletion of nucleotides 1-119 at the 5’ end of exon 2 and also to a frame shift 
and a premature stop codon in exon 2. mRNA with a premature stop codon is 
quickly degraded by the mRNA surveillance system called nonsense-mediated 
mRNA decay 32. It is likely that the aberrantly spliced TREM2 mRNA with the 
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premature stop codon was degraded by the nonsense-mediated mRNA decay 
pathway, hence less TREM2 mRNA was detected in TREM2 R47H ki mice. 
Thus, aberrant splicing-induced mRNA decay leads to TREM2 
haplo-insufficiency in TREM2 R47H ki mice. 
Although the R47H variant activates a cryptic splicing site in mice, no 
aberrant splicing was detected in human iPSC derived microglia-like cells and 
patient brains harboring the TREM2 R47H variant. As a result, the TREM2 
mRNA level remains unchanged in human microglia derived from induced 
pluripotent stem cells (iMG) harboring one TREM2 R47H allele. In addition, the 
expression of the R47H allele is comparable to the wt allele in iMG and patient 
brain samples. This finding raises the possibility that the R47H variant impairs 
TREM2 function by different mechanisms in humans and in mice. Using a 
cellular splicing assay, the splicing pattern of the human and mouse TREM2 
R47H variant was compared. The TREM2 R47H variant by itself is sufficient to 
induce aberrant splicing in mouse TREM2. However, neither the R47H variant 
nor silent mutations alter the splicing of human TREM2. In summary, TREM2 
R47H alters TREM2 splicing in mice but not in humans. This indicates that the 
TREM2 haplodeficiency phenotypes found in TREM2 R47H heterozygous AD 
mouse models 30 are not translatable to humans. Thus, humanized TREM2 
R47H mice with endogenous expression level should be generated to study 
the cellular consequence of the TREM2 R47H variant. Finally, my finding that 
the AD-associated variant R47H induces a mouse-specific reduction in 
TREM2 mRNA that does not apply to humans is highly relevant for 
TREM2-based therapy as ki mice are often used in pre-clinical studies.   
 - 149 - 
 
References 
1. Xiang, X. et al. TREM2 deficiency reduces the efficacy of immunotherapeutic amyloid 
clearance. EMBO Mol. Med. 8, 992–1004 (2016). 
2. Takahashi, K., Rochford, C. D. P. & Neumann, H. Clearance of apoptotic neurons without 
inflammation by microglial triggering receptor expressed on myeloid cells-2. J. Exp. Med. 
201, 647–57 (2005). 
3. Kleinberger, G. et al. TREM2 mutations implicated in neurodegeneration impair cell 
surface transport and phagocytosis. Sci. Transl. Med. 6, 243ra86 (2014). 
4. Hsieh, C. L. et al. A role for TREM2 ligands in the phagocytosis of apoptotic neuronal cells 
by microglia. J. Neurochem. 109, 1144–56 (2009). 
5. Colonna, M., Turnbull, I. & Klesney-Tait, J. The enigmatic function of TREM-2 in 
osteoclastogenesis. Adv. Exp. Med. Biol. 602, 97–105 (2007). 
6. Cantoni, C. et al. TREM2 regulates microglial cell activation in response to demyelination 
in vivo. Acta Neuropathol. 129, 429–47 (2015). 
7. Zhao, Y. et al. TREM2 is a receptor for β-amyloid that mediates microglial function. 
Neuron 97, 1023–1031.e7 (2018). 
8. Wang, Y. et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer’s 
disease model. Cell 160, 1061–71 (2015). 
9. Parhizkar, S. et al. Loss of TREM2 function increases amyloid seeding but reduces 
plaque-associated ApoE. Nat. Neurosci. 22, 191–204 (2019). 
10. Mazaheri, F. et al. TREM2 deficiency impairs chemotaxis and microglial responses to 
neuronal injury. EMBO Rep. 18, 1186–1198 (2017). 
11. Bohrmann, B. et al. Gantenerumab: a novel human anti-Aβ antibody demonstrates 
sustained cerebral amyloid-β binding and elicits cell-mediated removal of human 
amyloid-β. J. Alzheimers. Dis. 28, 49–69 (2012). 
12. Lathuilière, A. et al. A subcutaneous cellular implant for passive immunization against 
amyloid-β reduces brain amyloid and tau pathologies. Brain 139, 1587–604 (2016). 
13. Bard, F. et al. Peripherally administered antibodies against amyloid β-peptide enter the 
central nervous system and reduce pathology in a mouse model of Alzheimer disease. 
Nat. Med. 6, 916–9 (2000). 
14. Schenk, D. et al. Immunization with amyloid-β attenuates Alzheimer-disease-like 
pathology in the PDAPP mouse. Nature 400, 173–7 (1999). 
15. Paradowska-Gorycka, A. & Jurkowska, M. Structure, expression pattern and biological 
activity of molecular complex TREM-2/DAP12. Hum. Immunol. 74, 730–7 (2013). 
16. Crowley, M. T. et al. A critical role for Syk in signal transduction and phagocytosis 
mediated by Fcγ receptors on macrophages. J. Exp. Med. 186, 1027–39 (1997). 
 - 150 - 
 
17. Ulrich, J. D. & Holtzman, D. M. TREM2 Function in Alzheimer’s Disease and 
Neurodegeneration. ACS Chem. Neurosci. 7, 420–7 (2016). 
18. Guillot-Sestier, M.-V., Doty, K. R. & Town, T. Innate Immunity Fights Alzheimer’s Disease. 
Trends Neurosci. 38, 674–681 (2015). 
19. Fuller, J. P. et al. Comparing the efficacy and neuroinflammatory potential of three anti-β 
antibodies. Acta Neuropathol. 130, 699–711 (2015). 
20. Sevigny, J. et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. 
Nature 537, 50–6 (2016). 
21. Guerreiro, R. et al. TREM2 variants in Alzheimer’s disease. N. Engl. J. Med. 368, 117–27 
(2013). 
22. Jonsson, T. et al. Variant of TREM2 associated with the risk of Alzheimer’s disease. N. 
Engl. J. Med. 368, 107–16 (2013). 
23. N’Diaye, E.-N. et al. TREM-2 (triggering receptor expressed on myeloid cells 2) is a 
phagocytic receptor for bacteria. J. Cell Biol. 184, 215–23 (2009). 
24. Ulland, T. K. et al. TREM2 maintains microglial metabolic fitness in Alzheimer’s Disease. 
Cell 170, 649–663.e13 (2017). 
25. Mazaheri, F. et al. TREM2 deficiency impairs chemotaxis and microglial responses to 
neuronal injury. EMBO Rep. 18, 1186–1198 (2017). 
26. Atagi, Y. et al. Apolipoprotein E is a ligand for Triggering Receptor Expressed on Myeloid 
Cells 2 (TREM2). J. Biol. Chem. 290, 26043–50 (2015). 
27. Yeh, F. L., Wang, Y., Tom, I., Gonzalez, L. C. & Sheng, M. TREM2 Binds to 
Apolipoproteins, including APOE and CLU/APOJ, and thereby facilitates uptake of 
amyloid-β by microglia. Neuron 91, 328–40 (2016). 
28. Sudom, A. et al. Molecular basis for the loss-of-function effects of the Alzheimer’s 
disease-associated R47H variant of the immune receptor TREM2. J. Biol. Chem. 293, 
12634–12646 (2018). 
29. Song, W. M. et al. Humanized TREM2 mice reveal microglia-intrinsic and -extrinsic effects 
of R47H polymorphism. J. Exp. Med. 215, 745–760 (2018). 
30. Cheng-Hathaway, P. J. et al. The Trem2 R47H variant confers loss-of-function-like 
phenotypes in Alzheimer’s disease. Mol. Neurodegener. 13, 29 (2018). 
31. Isken, O. & Maquat, L. E. Quality control of eukaryotic mRNA: safeguarding cells from 
abnormal mRNA function. Genes Dev. 21, 1833–56 (2007). 
32. Maquat, L. E. Nonsense-mediated mRNA decay in mammals. J. Cell Sci. 118, 1773–6 
(2005).  
 - 151 - 
 
Acknowledgments 
I would like to express my sincerest thanks and gratitude to my supervisor 
Prof. Dr. Dr. h.c. Christian Haass for providing me the PhD candidate position 
and guiding me through my dissertation.  
I thank Prof. Dr. Harald Steiner and Dr. Arthur Liesz to be members of my 
Thesis examination committee. They always gave me guidance and many 
useful suggestions. I would like to thank Dr. Gernot Kleinberger for great help 
and countless discussions. I must also acknowledge Dr. Kai Schlepckow, Dr. 
Marc Suarez, Dr. Fargol Mazaheri, Samira Parhizkar, Dr. Anja Capell, Georg 
Werner for their valuable suggestions. They are a fantastic team to work with. 
Furthermore, I am grateful for my collaborators, Dr. Bernd Bohrmann and Dr. 
Irene Knuesel, who provided me with the valuable antibody and shared their 
thoughts. I wish to thank the GSN for providing me guidance and training 
during my PhD period. I furthermore want to acknowledge all readers of this 
thesis. Last but not least, I would like to give my sincere gratitude to my family, 
including my husband, who always support my research and give me 
numerous valuable suggestions and helped me through some tough moments; 
my parents, who live more than ten thousand kilometers away but always give 
me love and supports; my little daughter, who is my motivation to be better.  
  
 - 1 - 
 
Curriculum Vitae 
XIANG, Xianyuan   Date of birth: 08.01.1986   Nationality: P.R. China 
 
Education 
2013-2019 PhD candidate  
Graduate School of Systemic Neurosciences (GSN);  
Ludwig-Maximilians-University Munich (LMU), Munich, Germany 
2011-2013 Master of Biology ‘Molecular and Physiological Biology’  
Katholieke Universiteit Leuven, KU Leuven, Leuven Belgium 
2004-2008 Bachelor of Science ‘Biotechnology’ 
Shenzhen University, Guangdong China 
 
Research 
2013-2018 PhD thesis supervised by Prof. Dr. Dr. h.c. Christian Haass  
Topic: The role of TREM2 in pathogenesis and treatment of Alzheimer’s 
disease 
2011-2013 Master thesis supervised by Prof. Dr L. Arckens 
Topic: The age-dependent effect of monocular enucleation on the 
expression pattern of cytosolic and membrane proteins in mouse visual 
cortex 
2004-2008 Undergraduate thesis supervised by Prof. Dr. LIU, Shide 




Partial scholarship from Science@Leuven 
Outstanding Graduates Awards from Shenzhen University  
Top Prize of Shenzhen University Scholarship      
 - 2 - 
 
List of publications  
1. Xiang X, et al., The Trem2 R47H Alzheimer’s risk variant impairs 
splicing and reduces Trem2 mRNA and protein in mice but not in 
humans. Mol. Neurodegener. 13, 49 (2018). 
2. Xiang X, et al., TREM2 deficiency reduces the efficacy of 
immunotherapeutic amyloid clearance. EMBO Mol. Med. 8, 992–1004 
(2016). 
3. K. Zhu, Xiang X, Filser S, et al., β-Site amyloid precursor protein 
cleaving enzyme 1 inhibition impairs synaptic plasticity via seizure 
protein 6. Biol Psychiatry. 83(5):428-437 (2018). 
4. G. Kleinberger, Brendel M, Mracsko E, Wefers B, Groeneweg L, 
Xiang X, et al., The FTD-like syndrome causing TREM2 T66M 
mutation impairs microglia function, brain perfusion, and glucose 
metabolism. EMBO J. 36, 1837–1853 (2017). 
5. Ardura-Fabregat A, Boddeke EWGM, Boza-Serrano A, Brioschi S, 
Castro-Gomez S, Ceyzériat K6, Dansokho C, Dierkes T, Gelders G, 
Heneka MT, Hoeijmakers L, Hoffmann A, Iaccarino L, Jahnert S, 
Kuhbandner K, Landreth G, Lonnemann N, Löschmann PA, McManus 
RM, Paulus A, Reemst K, Sanchez-Caro JM, Tiberi A, Van der Perren 
A, Vautheny A, Venegas C, Webers A, Weydt P, Wijasa TS, Xiang X 
et al., Targeting Neuroinflammation to Treat Alzheimer’s Disease. 
CNS Drugs.31 (2017) pp.1057-1082 
  
 - 3 - 
 
Eidesstattliche Versicherung / Affidavit  
Hiermit versichere ich an Eides statt, dass ich die vorliegende Dissertation 
‘The role of TREM2 in pathogenesis and treatment of Alzheimer’s disease’ 
selbstständig angefertigt habe, mich außer der angegebenen keiner weiteren 
Hilfsmittel bedient und alle Erkenntnisse, die aus dem Schrifttum ganz oder 
annähernd übernommen sind, als solche kenntlich gemacht und nach ihrer 
Herkunft unter Bezeichnung der Fundstelle einzeln nachgewiesen habe.  
I hereby confirm that the dissertation ‘The role of TREM2 in pathogenesis 
and treatment of Alzheimer’s disease’ is the result of my own work and that I 
have only used sources or materials listed and specified in the dissertation. 
München, den 26.07.2019 
Munich, date 26.07.2019 
Unterschrift  Signature  Xianyuan Xiang 
  
 - 4 - 
 
Declaration of author contributions 
Paper I: X.X. G.K. and C.H. designed the study and interpreted the results. 
X.X. performed all experiments except generating mutant N9 cells, which was 
performed by G.W. and A.C., the quantification of cell surface Fcγ-receptors 
expression level was done by A.L.; B.B. and I.K. provided antibodies. R.F. 
generated monoclonal antibody against TREM2 (clone 5F4). F.M. and G.K. 
provided bone marrow cells. C.H. wrote the manuscript with input of all 
co-authors. 
Paper II: X.X. designed and conceived the study. C.H. and X.X. 
interpreted the results. C.H. and X.X. wrote the manuscript with input from all 
co-authors. B.W. and W.W. generated the TREM2 R47H knock-in mice. G.K. 
and B.W. analyzed potential off-targets. X.X., K.Z. and J.H. prepared bone 
marrow and isolated microglia from mice. X.X. and B.B. performed RNA 
analyses and immunoblotting. X.X. performed RT-PCR, allele specific qPCR 
and cellular splicing analysis. T.P., A.M. and J.P. generated the iPSC derived 
microglia-like cells and performed qPCR on these cells. M.C. and W.S. 
provided the mouse brain samples from humanized TREM2 mice. 
Munich 01.08.2018 
Signature: 
Xianyuan Xiang        Prof. Dr. Dr. h.c. Christian Haass 
